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SUMMARY
Acidic non-steroidal anti-inflammatory agents repre­
sent a large group of closely related compounds prescribed 
for the many patients suffering from rheumatic diseases. 
The mode of action of this group of drugs has been related 
to prostaglandin synthetase inhibition. This action is 
non-specific and may also be responsible for the gas­
tric irritation and bleeding which constitute' a major side 
effect. It is important therefore for patients being 
treated with such non-specific high dosing agents to be 
far better controlled than they are at present. Methods 
providing simple, rapid analysis of body fluids must be 
developed and adapted for routine use in clinical situa­
tions. These techniques are also necessary for an inves­
tigation into possible reasons for disparate drug activi­
ties observed in patients with rheumatic disease respond­
ing differently to different acidic drugs.
The technique of High Pressure Liquid Chromatography 
(HPLC) has been explored as a means to these ends. The 
novel procedure of 'ionic suppression' in HPLC employing 
a reversed phase column and aqueous acidic solvent, based 
upon the physico-chemical properties of the acidic anti­
inflammatory agents studied, has been developed for 
routine use. The procedure has been found to afford
Ill
flexibility, selectivity, load capacity, sensitivity, 
speed and convenience over previously reported analytical 
methods. It is also capable of being exploited in the 
analysis of newly developed related drugs.
The results obtained from the application of the 
HPLC procedure developed have been;-
(1) the determination of ten non-steroidal anti­
inflammatory agents in plasma and urine,
(2) the application in a clinical trial of Benoxa-
profen,
(3) the assistance to clinicians at the Royal 
National Hospital for Rheumatic Diseases in providing 
rapid evaluation of patient compliance,
(4) the simultaneous determination of four non­
steroidal anti-inflammatory agents and their metabolites 
in plasma and urine,
(5) the profile study of levels of Sulindac and its 
metabolites in the plasma of a healthy volunteer after a 
single oral dose over 24 hours,
(6) the examination of clinical urine and plasma 
samples of a patient treated with Clinoril and naproxen,
(7) the separation of the glucuronide conjugates of 
ketoprofen and benoxaprofen,
(8) the detection of hydroxyketoprofen as.a meta­
bolite of ketoprofen in rabbit.
IV
HPLC techniques, have thus be en established by 
this study as a most valuable aid to the modern therapy 
of rheumatic diseases. Improvements in detector techno­
logy will afford greater sensitivity and should extend 
the scope of its therapeutic applications.
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IN T R O D U C T I O N .
CHAPTER 1
Non-Steroidal Anti-Inflammatory Agents
Acidic non-steroidal anti-inflammatory agents repre­
sent a large group of closely related compounds pre­
scribed for the many patients suffering from rheumatic 
diseases. These drugs possess both anti-inflammatory 
and analgesic properties, and also exhibit a range of 
side effects. Rheumatic diseases may have a minor or 
major effect upon an individual's health and treatment is 
largely an attempt to subdue inflammation, limit defor­
mity and relieve pain. The evaluation of the available 
drugs in order to offer the patient the most efficacious 
treatment is a continuous process generally carried out 
by the patient, the general practitioner ,and^  in severe 
cases, by the consultant rheumatologist under hospital 
conditions. It is here that recently introduced drugs 
are evaluated and compared with existing therapy.
Plasma and urine levels of therapeutic agents and 
sometimes their metabolites may be related to clinical 
efficacy. Determination of such levels in hospitals is 
not yet a routine procedure, and for high dosing drugs 
such as non-steroidal anti-inflammatory agents, this could 
lead to poor disease control and harmful side effects.
The most obvious biological feature of acidic non­
steroidal anti-inflammatory agents is their lack of 
specificity of action. Their broad spectrum of biological 
responses, many of which may be unrelated to their desir­
able response, accounts largely for their non-specific 
clinical efficacy and for some side effects. Most acidic 
agents, for example, inhibit a number of proteolytic 
enzymes including collagenases (1), they uncouple oxida­
tive phosphorylation (2), bind strongly to protein and 
displace endogenous substances from serum protein binding 
sites (3). They inhibit the biosynthesis of mucopoly­
saccharide and act as strong inhibitors of prostaglandin 
synthetases (4, 5)« If this mode of action is non­
specific, ■ then side effects, especially gastric irri­
tation due to a decrease in prostaglandin synthesis in 
the lining of the gut would lead to gastric hyperacidity.
Clearly, it is important for patients being treated^ 
with these non-specific, high dosing agents to be far 
better controlled. As for such control, methods provid­
ing simple, rapid analysis of body fluids must be devel­
oped and adapted for routine use in clinical situations.
Based upon the structure of indomethacin, a powerful 
anti-inflammatory agent, a whole range of aromatic acetic 
acid derivatives has been developed. Furthermore, pat­
ients with^rheumatic disease appear to respond differently
to different acidic drugs. Hence, the development of 
appropriate analytical techniques is necessary for an 
investigation of possible reasons for disparate drug 
activities.
1.1 Pharmacological Actions.
The major parameter in the design of new anti­
rheumatic agents acting via new mechanisms is the 
definition of a meaningful animal or in vitro disease 
model. All available biological test systems are likely 
to identify those agents acting by the mechanisms of 
existing drugs. Most of these agents combat a part of 
the normal inflammatory response and are best described 
therefore as anti-inflammatory agents. Such drugs treat 
symptoms only, that is, relief of pain, maintenance of 
function and prevention of progressive anatomical deformity
Inhibition of prostaglandin is now considered to be 
the most important mode of action of these drugs. Vane (4) 
in 197Î first proposed that anti-inflammatory drugs, 
including aspirin, operate by inhibiting prostaglandin 
synthesis. It was also revealed that:-
(i) Prostaglandins were likely to be important in 
all body functions that are modified by aspirin-like 
drugs.
(ii) Intermediate prostaglandin synthesis may also 
have important functions.
(iii) Prostaglandins are the body's natural defences 
against all forms of change, including those induced by 
mechanical, pathological, chemical and physiological 
stimuli. Although inflammation is a defence mechanism,
it can become pathological. Prostaglandins are known to
......................
induce inflammation in rats and man.
(iv) Finally, the concentrations of unmetabolised 
aspirin-like drugs found in blood plasma following clini­
cal doses were similar to the concentrations needed in 
vitro to inhibit prostaglandin synthesis.
Crook and Collins (6) measured prostaglandin synthe­
tase activity in vitro in the microsomal fraction of 
synovial tissues from rheumatoid arthritic patients. The 
enzyme was inhibited in vitro by low concentrations of 
several 'aspirin-like' drugs, although paracetamol and 
salicylic acid were virtually inactive. It was also 
illustrated that many non-steroidal anti-inflammatory 
drugs were more potent inhibitors of the enzyme system, 
prostaglandin synthetase, than aspirin.
Many thousands of arylacetic acids have now been 
synthesised and certain molecular features have emerged 
for compounds with an optimum therapeutic index. From 
the list of structures of the drugs studied (figs. 3- lA 
and IB), an oc-methyl group not only enhances anti-inflam­
matory activity considerably, but endows the molecule with
an asymmetric carbon atom. This affords two geometric 
forms of the drug each of which may interact differently 
with the 'receptor' or 'receptors'. Drug geometry as in 
many other series of therapeutic agents, appears to be 
important and dextrorotatory agents (S (+) configuration) 
appear to possess higher in vivo activity than their mir­
ror image form, eg., especially in the case of naproxen, 
suggesting that at least some receptors are selective. 
There is: certainly high specificity of the S(+) isomers 
of arylacetic acids in their inhibition of prostaglandin 
synthetases.
Whatever the modes of action of these drugs, there 
is a need for the drug to be present in a therapeutic 
concentration at the site of action. Currently, the con­
centration in blood is used as a guide to therapy. It is 
also the only measureable parameter that may indicate the 
fate of the drug in the patient.
1.2 Side Effects.
The non-steroidal anti-inflammatory drugs are used 
to treat chronic conditions and high doses are usually 
required. A range of undesirable side effects including 
dyspepsia, skin rashes, gastric irritation and bleeding, 
and central nervous system toxicity, especially headaches 
and dizziness, have been well documented by Prescott (7).
The 'acidic' anti-inflammatory agents which include 
aspirin, arylacetic acids, phenylbutazone and its analogues 
and the fenamic acids have all been haunted by the spectre 
of gastric irritation. Attempts to mask the acidity, 
however, by employing groups other than carboxylic acid 
groups have met with little success, for example, intra- 
zola employing the acidic tetrazble moiety and bufexamac 
with a hydroxamic acid function, fig;.- 1.2.









A number of anthranilic acid anti-inflammatory 
agents known collectively as fenamates, fig. 1.3» could 
conceivably be related' to aspirin. Gastric irritation 
together with other toxic manifestations, eg., papillary 
necrosis in animals, renders the fenamates the least 
popular group of acidic anti-inflammatory agents.




It is possible that the ability of acidic anti­
inflammatory drugs to inhibit non-specific prostaglandin 
synthetases is the very property that results in gastric 
irritation, for decreased prostaglandin biosynthesis does 
lead to gastric hyperacidity and it is likely that local 
release of prostaglandins plays an important role in 
gastric secretion control. The claims of greater effi­
cacy and safety made for newer agents marketed cannot be 
wholly justified unless it is possible to design acidic 
agents that are selective inhibitors of prostaglandin 
synthetases.
8There is however, a second group of drugs that not 
only offer symptomatic relief but retard the disease by 
attacking the causative chronic inflammatory processes. 
These include D-penicillamine, levamisole, gold compounds, 
and some anti-malarials such as chloroquine and hydroxy­
chloroquine. These drugs are often slow in their onset 
of action and are sometimes accompanied by severe side 
effects. They therefore require careful patient monitor­
ing.
1.3 Excretion.
Most of the non-steroidal anti-inflammatory drugs 
are excreted as glucuronide conjugates. However- a few, 
including Indomethacin, Naproxen, phenylbutazone and 
Sulindac undergo metabolism before conjugation as shown 
in Table 1.1 and fig. 1.4A & B. The primary metabolites 
of indomethacin and naproxen are inactive. Phenylbuta­
zone is metabolised into oxyphenbutazone and hydroxy- 
phenylbutazone. Oxyphenbutazone is a very potent metabo­
lite and is also administered as a drug alone. The sul­
phide metabolite of Sulindac is more potent and even has 
a longer half-life in plasma than sulindac itself. It is 
not excreted in urine but converted to the sulphone meta­
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1.4 Methods of Analysis»
Various chromatographic and spectrophotoraetric 
methods of analysis have been used to identify and deter­
mine these non-steroidal anti-inflammatory agents.
In 1953» Burns et al. (13)'applied UV spectrophoto­
metry to the analysis of phenylbutazone extracted into 
hexane from acidified plasma and urine. The phenylbuta­
zone was removed from the hexane using aqueous alkali and 
the UV absorbance determined at 265nm. The method was 
later applied to metabolites of phenylbutazone extracted 
from biological fluids (11). The UV spectra for ketopro­
fen, naproxen and fenoprofen were published by Lotti (l4) 
in 1975* Each compound was dissolved in methanol and the 
absorbances measured between 220 and 320nm. This data 
provided a method for identification and possible quanti­
tative determination of these agents.
Hucker, et al.(15) measured indomethacin by spectro- 
photofluorimetry at an excitation maximum of 295 and 
emission maximum of 385nm.
Harman, et al.(8) investigated paper and thin-layer 
chromatographic separations of urinary metabolites of 
indomethacin. The separation of indomethacin, its meta­
bolites and their glucuronide conjugates was obtained on 
Whatmann 3MM paper with methanol-water-n-butylalcohol- 
benzene (2:1:1:1) as the solvent. The thin-layer
13
chromatographic behaviour of naproxen, ketoprofen and 
fenoprofen had also been reported (14). These methods, 
though not quantitative could be used for preliminary 
identification and preparative analysis to obtain pure 
compounds for further studies.
More accurate, specific and sensitive methods of 
analyses of these agents were needed for pharmacological 
and pharmacokinetic studies. Various gas chromatogra­
phic procedures were developed for some of these compounds 
and the conditions used are summarized in Table 1.2.
From this table, it can be seen that:
(i) Derivatization of the free acid was usually 
necessary, either to the methylester or to the trimethyl- 
s hlyl ester. The latter would improve the volatility
of the compound. Phenylbutazone is not structurally ' 
suitable for derivatization, and consequently is less 
readily detected.
(ii) The stationary phases used are generally non­
polar, SE-30, Apiezon-1; to slightly polar, OV-l?,
XE-60.
(iii) The detection by FID is usually sensitive 
enough for quantifications in plasma, especially when 
derivatives were formed. However, detections by ECD used 
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In general, sample preparation is a significant part 
of analyses because of the series of extraction procedures 
and the need for derivatization. Finally, analysis at 
such high temperatures might result in decarboxylation 
of some of the drugs.
The only ion-exchange chromatographic method reported 
was for naproxen (23). Urine composite aliquots were 
pipetted onto a 35x1.8 cm.id column charged with 35meq. of 
ion exchange resin. The biotransformed components related 
to naproxen were then separated by successive elution with 
different buffers, over a pH gradient from 3*5 to 6.5» 
About twenty bio-transformed products of Naproxen were 
detected in human and animal studies.
The technique of HPLC was introduced for the analy­
sis of these agents in 1974? Pound, et al. (24) 
described a method for the assay of phenylbutazone in 
plasma. Phenylbutazone was extracted into n-hexane from 
acidified plasma and chromatographed on a Sil-X adsorbent 
column with 10^ tetrahydrofuran in n-hexane as the mobile 
phase. The detection was by a UV-monitor at 254nm and the 
limit detected was 0.2^g/ml. By using the same station­
ary phase and a slightly modified mobile phase containing 
0.002^ acetic acid and 23^ THF in n-Hexane, the simultan­
eous determination of phenylbutazone and its metabolite, 
oxyphenbutazone was achieved (25)• Both procedures,
16
though more sensitive than the previously reported GC 
methods (21,22), still involved extraction of the drugs 
into organic solvents because the stationary phase used 
was not compatible with aqueous samples.
An attempt to minimize sample preparation led to the 
development of a reversed phase HPLC procedure to determine 
indomethacin in a mixture of indomethacin, frusemide and 
aspirin. Aqueous and slightly acidic acetonitrile (pH_5) 
was the solvent pumped through a column, (60.93 x 0.21 cm. 
id), dry-packed with Bondapack 18. Initial extraction 
of indomethacin from plasma was still necessary with the 
extract reconstituted in the mobile phase before injection 
on to the column (26). This procedure has been found to 
produce a broad peak for indomethacin. The peak was how­
ever improved at a lower pH of 3 employed in this work.
17
CHAPTER 2
The Technique of High Performance Liquid
  Chromatography
2.1 Perspective
HPLC has become a major analytical technique in the 
fields of Pharmacy, Biochemistry and Chemistry. Chroma­
tography in its many forms is basically a separation 
technique. Separation is achieved through a differential 
migration process whereby the sample components are 
selectively retained or delayed by the stationary phase.
The sample mixture is introduced onto a bed of stationary 
phase, and swept through it by mobile phase at a rate 
dependent upon the mutual interactions of sample com­
ponents with the stationary phase and the mobile phase. 
Generally, these interactions differ in magnitude for the 
different sample components so that their rate of passage_^ 
through the stationary phase bed differs and separation is 
thus achieved.
Stationary phases largely promote separation of 
molecules by one or more of the four basic retention 
mechanisms, namely:-
(i) Adsorption: the ability to physically sorb 
solutes from solution.,
(ii) Partition: the ability to dissolve solutes 
when contacted with solutions in an immiscible solvent.
18
(iii) Ion exchange, the ability to chemically sorb 
solutes from solution; and
(iv) Gel permeation; a process structure which can 
retain some, and reject other, solutes on the basis of 
solute size or shape.
Thesefour retention mechanisms are available to 
users of HPLC technique, plus a rapidly expanding range 
of bonded phase materials that include the reversed phase 
packings. Therefore, the separating potentials of HPLC 
is probably greater than in any other chromatographic 
technique.
The different retention mechanisms all have one 
feature in common, namely that a mixture of solute com­
pounds is separated into individual component bands or 
peaks, to produce the chromatogram. The interpretation 
of the chromatogram provides the basis for the utiliza­
tion of the technique qualitatively and quantitatively.
2.2 Definitions and Nomenclature of Chromatography. ± 9
2.2.1. Retention Parameters.
In a given chromatographic system, the time taken 
and the volume of mobile phase required to elute a speci­
fic solute from the stationary phase bed is constant. 
Therefore the time or volume needed to elute one sub­
stance relative to another particular compound will also 
be constant. The'se facts lead to considering two aspects 
of retention in chromatography:-
(a) Various methods of describing retention and 
their inter-relations, and
(b) The use of retention as means of the identifica­
tion of solutes.
Retention parameters can be measured in two ways : -
2.2.1.1 Column Capacity Ratio, K'.
It is a measure of the ratio of the amount of solute 
in the stationary phase compared to the mobile phase. It 
is proportional to .the distribution coefficient K and the 
volumes of stationary and mobile phases. Vs and Vm respec­
tively.
K ’ = K. Vs   (1)
Vm
The average fraction of time spent by a molecule in the
stationary phase = K*   (2)
1+K'
and in the mobile phase = 1   (3)
1+K'
20
K' can be expressed as
K' = tR-tRo 
tRo
tR and tRo are readily obtainable for any solute from the 
chromatogram, figure 2,1»
FIGURE 2.1
 t R l _____
Detector
Response




tR = Retention time of the solute; it is the period 
of time required for the solute to pass from the injector 
through the column and the detector. It is measured 
directly on the chromatogram from the point of injection 
to the apex of the solute peak and is expressed in mins. 
or mm.
tRo = Retention time Qiistance^ of an unretained com­
pound usually taken as the first peak to emerge. It is 
generally the solvent in which the solute was dissolved. 
For reversed phase materials, KNO^ is suitable.
K’ = Vr-Vm    (5)
Vm
Vr = Retention or elution volume of the solute.
Vm = Total volume of mobile phase in the column 
including pores, and is given by:-
tRo X f = the volumetric flow rate.
K' is therefore the measure of number of column 
volumes needed to elute the solute. It can be seen that 
K' increases by 1 for each 'Column Volume' needed to 
elute the solute. It is linear with time, volume and 
chart distance.
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2.2.1.2 Retention Ratio, R.
This is the fraction of solute in the mobile phase.
R = 1 = tRo = Vm = ^    (6)
1+K' tR Vr Zf
where Zo = The distance travelled by the solvent,
Zf = The distance travelled by the solute on a
column, plate or paper.
Retention on columns is measured by R, while on TLC
and paper by Rf, i.e. Zo.
Zf
Thus K'= 1:^   (7)
R
2.2.2 Column Efficiency.
This is the ability of the column to minimise peak 
spreading. It is expressed quantitatively as the number
of Theoretical Plates (N) which is derived from peak width
and retention time;
From figure 2.1;
N = 16 ItRl^ = j.54rtRl2   (8)
LwtJ [wîJ
where Wf = the peak width at half the peak height and 
is a measure of the peak shape.
The characteristic of a column is more precisely 
defined by using the Height Equivalent of a Theoretical 
Plate (HETP), commonly referred to as Plate Height (H), 
and is expressed as
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H(min) = Length of the Column (mm)
N
H is smaller for (i) better columns,
(ii) small particle diameter,
(iii), less viscous solvents,
(iv) higher-temperaturesr
(v) small solute molecules,
(vi) slow flow rate.
The lower the value of H - generally between 0.01 
and 0.08mm, the better is the column performance.
2.2.3 Band Broadening.
When a small volume of solute is injected sharply 
into a column, the solute spreads out gradually as it 
migrates. If the distribution ratio K is independent of 
concentration, then the concentration profile assumes the 
Gaussian shape, and the relationship between solute con­
centration in mobile and stationary phases is linear.
Figure 2.2 shows basic isotherm shapes and their 
effect on peak shape and on retention time. Reducing 
solute size improves tailing and fronting. The slope of 
the graph is the capacity factor, R; and the point D, 
indicates the limit of linear behaviour for B and C.
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The mobile phase could be a gas as in GC or a liquid 
and the relative order of magnitude of their physical con­
stants are compared in Table 2.t.
TABLE 2.t
Physical Constants Gas Liquid
Diffusion Coefficient, Dm, Cm^S~^ 10-1 10"-^
Density, ^ , gCm"^ lQ-3 1
—1 — 1Viscosity,-^, g Cm" S" 10-4 10"2
Reynolds' Number 10 100
2.2.3.1 Eddy Diffusion,
The velocity of a solute molecule passing through a 
packed column will vary greatly according to the flow 
path in which it happens to be. Additionally, solute 
molecules may transfer laterally by diffusion and by con­
vection from one flow path to another. This coupling of 
eddy and lateral diffusions results in a decrease in the 
amount of band broadening.
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2.2.3.2 Longitudinal Molecular Diffusion.
This is a very important factor in increasing hand 
broadening at low flow rates in GC, due to the high value 
for Dm, whereas in HPLC, it is so small that it can be 
ignored. The contribution that it makes to the plate 
height is expressed by
2YDm   (9)
where u = Flow velocity
'f - Factor indicating the degree to which diffusion 
is obstructed by the column packing. It is <1, 
for HPLC it is about 0.6.
Dm = Diffusion Coefficient of solute in the mobile 
phase.
In GC, Dm is reduced at higher flow rates and lower 
temperatures, hence the effect of temperature upon 
resolution.
2.2.3.3 Mass Transfer.
This takes place in:-
1. The Stationary Phase:- It is the rate at which 
solute molecules transfer into and out of the stationary 
phase. In a liquid stationary phase, the rate of diffus­
ion through the liquid layer controls the rate of mass 
transfer. Thin layers of low viscosity give higher rates, 
but solid supports must not be exposed. It is expressed 
as ; -
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K* .-d^u   (10)
(l+K-) Ds
or
Cs . dfu   (11)
Ds
where Cs = A constant ot to the retention ratio and shape
of the column packing.
d = Thickness of liquid stationary phase.
Ds = Diffusion coefficient of solute in the
stationary liquid phase.
2. Mobile Phase - Movement of solute molecules in
the mobile phase at different speeds due to the different
paths followed increases band broadening. Coupling the
contribution from eddy diffusion with that from lateral
transport diffusion gives the relationship,
=  1    (12)
1 + Dm
2/^ dp Cmdp^u
where A = a constant depending on packing structure, 
dp = particle diameter.
Cm = a function of the packing structure and 
cqlumn dimension.
The presence of 'stagnant' mobile phase occurring in 
the less accessible regions of the totally porous station­
ary phases also increases band broadening. Its contribu­
tion to H is measured as
Csm . dp^ . u   ( 13 )
Dm
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where Csm is a function dependent upon the fraction of 
total mobile phase that is considered to be 
stagnant.
Thus in HPLC, it is very important that the particles 
are porousand the. pores* are uniform with a minimum of 
poorly accessible areas.
2.2.3.4 Expression for Plate Height, H.
The sum of all these contributory factors provide a 
value for H, i.e.
H = 2YDm + Csd^u +________ 1______  + Csmd^u _( 14)
Ù Ds 1 + Dm Dm
I 2A.dp Cmdp^u |
Longitudinal Mass Eddy Lateral Mass




Equation 14 is a development of the van Deemter (2?) 
equation developed to consider the factors determining H 
in GC. Often simplified to
H = A + B + C.u 
u
[15]
the new equation simplifies to
■“ *  [ i  *  c f c r ‘—
H = B + Cs.u + Csm
_ u
Comparing GC and HPLC for H and u (figure 2.3)» in 
GC, the optimum gas flow rate for maximum resolution is 
when H is at minimum. Flow rates below this give poor H
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values due to an increase in longitudinal diffusion;
Hence analyses are performed above the minimum flow rate.
In HPLC, in practice, low flow rates may be used without 
incrising H seriously.
The performance of different particle sizes may be 
compared using the reduced parameters proposed by Knox (28)
where Reduced Plate Height h = H_
dp




The general relationship of reduced plate height and 
reduced velocity may be simplified to
---------------  [19]












2.2.3»5 Extrabed Contributions to Band Spreading.
The final concentration profile of the solute in the 
chromatogram as revealed by the detector also includes the 
contribution of other factors. These are mainly:
(1) The sharpness of the sample concentration pro­
file at the start of the chromatography due to mode of 
injection.
(2) Non-linearity of solute distribution between 
stationary and mobile phase as a function of concentra­
tion, and
(3) Change in solute band shape after chromatography 
due to the connections between the column and detector, 
and also due to the detector cell volume.
2.2.4 Resolution, Rs.
This is a measure of the separation between two adja­
cent bands, and is defined as the distance between the 
two band centres divided by the average band width, 
figure 2.1.
Rs = tRg-tR^   (20)
i[w^+w^
when Rs 0.8,<the separation is<95^.*
1.0,^ the separation is 98 .^
1.3,*the separation is complete.
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Resolution may also be written as
Rs =VNnC'o-KM (21)F'2-K'il 
L 1 + k J
= v^ibrinr K’p ]   (22)
where ct- Selectivity Factor [%]
These are the factors affecting resolution and they 
are essentially independent so that each may be optimized 
in turn: -
ot- The most important factor and is determined by 
the combination of the packing material and the 
eluent system.
K* - Resolution is improved by increasing K', and the 
effective range is 1-10. It is altered by 
changing the eluent strength in HPLC, while in 
GC by altering the temperature.
N - Column efficiency expressed as the plate number.
Because Rs^ S/tT, a large increase in N is needed to
significantly improve Rs. Since N = L, N can be increased
H
by using a longer column, although band spreading will 
also increase.
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2.3 Bonded Phase Liquid-Liquid Chromatography.
Most of the problems associated with classical LLC 
have been overcome by the development of support mater­
ials containing chemically bonded polar or non-polar 
groups that are unaffected by solvent changes. This is 
a major advance in the technique of HPLC because of its 
relevance to the selectivity of the separation process.
FIGURE 2.5 Retention Mechanisms in HPLC.
HPLC
Adsorption Bonded lases (LLC) Ion Exchange Gel Permeation




The bonds are commonly produced by silylation of the 
free silanol groups that occur over the surface of silica, 
using reagents devised for GC.
=  Si-OH+R^SiCl ► =Si-0-SiR^
A Monochloro-Organo Silane.
Methoxy or ethoxy silanes are the most reactive of 
the silanes. Further reagents are used to extend this
3 3
bond to produce chains of the required length and func­
tional groups, figure 2.6, The bond resulting from the 
silylation reaction is the siloxane bond;
=  Si - 0 - Si= 
which is thesame as occurs within the silica support 
material. It is stable to mobile phases between pH 2 and 
8, but above this range, the silica material will dis­
solve in the mobile phase.
2.3.1 Reversed Phase Material.
The entire surface of the silica including pores 
within the particle, is chemically bonded with hydro­
carbon chains, figure 2.6B, eg., C2, 6, 8 or 18. OCTADE- 
CYL (C18) is the most commonly used, although different 
commercial forms vary according to:-
(1) Percentage {%) carbon loading;
Partisil - lO-ODS 5^
Spherisorb — 3“0DS 7 %
Hypersil — 5“0DS l6fc
RP-18 Monomeric brush Z0%
Partisil — 10—ODS—2
Polymeric brush 20 .^
(2) Whether the remaining free silanols are silylated 
i.e. 'capped' or not, figure 2.7. The extent of capping 
depends on accessibility to the silylating reagent, and 
100# capping is not possible because of steric hindrance
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FIGURE 2.7 Surface of Reversed Phase Material» 35
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The slight variations in properties of the various 
commercial forms of these phases provides further flexi­
bility in the choice of packing material for a particular 
separation.
2.3.2 Solvent Interaction With the Bonded Phase.
For all reversed phase materials, the surface is 
predominantly hydrophobic, and is used with an aqueous 
mobile phase containing an organic modifier, usually 
methanol or acetonitrile. Under these conditions, the 
uncapped surface hydroxyls are highly solvated with water 
and so are deactivated. Hence, a solute molecule must be 
able to displace a solvent molecule in order for reten­
tion to occur by adsorption. Many of the surface hydrox­
yls will be inaccessible due to steric hinderance by the 
brush.
Scott and Kucera (29) have shown for methanol, 
acetonitrile and isopropanol that reversed phase mater­
ials adsorb a layer of solvent from the aqueous mobile 
phase, provided the amount of solvent in the mobile phase 
is enough to wet the surface of the bonded phase.
The amount of solvent adsorbed did not vary with the 
concentration of solvent present and calculations strongly 
suggested that the adsorbed solvent layer is only a mono­
layer.
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2.3.3 Solute Interaction With the Surface of the Bonded 
Phase >
The same authors (29) also concluded that for solutes 
eluted with. K* values of up to 10  ^the mono-molecular 
layer of solvent is not displaced by the solute. Thus in 
chromatographic development^ solute retention must involve 









Monolayer — ; 
Solvent
^Stationary Phase
Horvath and Me lander (30A) have summarized inter­
actions that aid retention, and these are illustrated in 
figure 2.8.
Interactions that aid retention of solute:-
(i) Association of brush and solute due to hydro- 
phobic interactions causes a decrease in the molecular
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surface area exposed to the solvent. Therefore an in­
crease in % carbon loading and carbon chain length will 
increase retention.
(ii) Increase in hydrophobic area of solute, and
(iii) Increase in surface tension of the solvent.
Interactions that aid elution of solute:-
(i) Attractive interactions with the solvent,
(ii) A solute substituted with a polar functional 
group will enhance solute-solvent interactions compared 
to the unsubstituted form.
2 .3.4 Choice of Mobile Phase.
The mobile phase in bonded phase LLC usually consists 
of relatively small organic molecules or a mixture of 
several such materials. There is a need to use low- 
viscosity liquids in order to minimize the driving pres­
sure required to force it through the packed bed. An 
increase in mobile phase viscosity also increases the 
analysis time.
The solvent strengths are usually measured 
in terms of the solvent polarity and are presented as an
eluotropic series (31-35)» However, solvents in a 
series with comparable polarity rankings may have differ­
ent solubility parameters. However, the eluotropic series 
is a useful means of ranking the relative polarities of 
solvents, and it is in common use.
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Thus the most important practical point stemming 
from consideration of column dynamics is to choose a 





The mode of action of non-steroidal anti-inflammatory 
drugs has been linked with the inhibition of prostagland­
in synthetase. This is a non-;:Specific .^action and so 
contributes to the side effects of the drug administered.
It is therefore important for patients being treated with 
these non-specific, high dosing drugs to be under better 
clinical control. Thus there is a need for a rapid tech­
nique of assessment of these agents in body fluids and 
suitable for routine use in clinical situations.
The wide range of non-steroidal anti-inflammatory 
agents available often leads to multiple drug therapy 
with potentially dangerous consequences. A selective 
method of monitoring two or more of these drugs simultané 
eously would be an advantage. This would also reveal 
those patients that employ self medication with related 
agents such as paracetamol or aspirin, without the know­
ledge or perhaps agreement of the clinician.
Furthermore, such a simple and accurate method of 
body fluid analysis is likely to improve our knowledge 
of pharmacokinetic parameters, of each drug in the 
patient, and this could then be related to therapy. The 
result would be
(i) Optimization of the dose for each patient.
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thus hopefully minimizing the side effects, and
(ii) An indication of the drug of choice for a 
specific patient.
3.1 Drugs Studied.
The non-steroidal anti-inflammatory agents chosen 
for this study were selected because they are being 
employed, or are undergoing clinical trials, at the Royal 
National Hospital for Rheumatic Diseases, Bath. All the 
clinical samples of urine and plasma were obtained from 




(ii) Benoxaprofen: ( + )2-f^-chlorophenyl)-ot-methyl- 
Sr^ berrzoxane acetic acid (36,37)*
(iii) Diflunisal: 5~(2,^-difluorophenyl) salicylic 
acid (38,39).
(iv) Fenoprofen:( + )2-^3“Phenoxyphenyl^propionic acid
(40.)
(v) Indomethacin: l-p-chlorobenzoyl-5-methoxy-2- 
methyl-indoleacetic acid (13,41).
(vi) Ketoprofen; ( + )2-^3-BenzoylphenylJpropionic 
acid (42,43).
^ 2 FIGURE 3«1A Structures of the Drugs.
Cf CHî COOH
H , C = C H C H 20 Alclofenac
CH3














FIGURE 3.IB Structures of the Drugs (cont'd.)
Indomethacin.















(vii) Naproxen: (+)6-Methoxy-a-methyl-2-naphthalene 
acetic acid (9,10,44).
(viii) Sulindac: (Z)-5-fluoro-2-methyl-l-4-methylsul- 
phinylhenzylidene-3-acetic acid (12).
3.1.2 Amidic Acids:
(i) Phenylbutazone: 3,3-dioxo-4-n-butyl-l,2- 
diphenylpyrazolidine (13).
Their structures are illustrated in fig. 3*1 A&B. 
Physicochemicaily, these compounds are moderately 
lipophilic weak acids with pka values between 4.5 and 
7.5' Their solubility in water is pH dependent, 
whilst■ they?:are readily soluble in organic solvents.
They are also extensively bound to plasma protein. 
Compilation of the physical- data for these compounds have 
already been published (45).
They all possess strongly absorbing UV chromophores, 
and have absorption maxima between 240 and 320mm. The 
absorption is enhanced in acidic conditions, because they 
exist in these non-ionic forms, and at 254mm, it is con­
siderable for all of them., A variable wavelength UV- 
monitor is therefore the detector of choice.
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3.2. Choice of Technique.
HPLC appeared to be the technique of choice because 
it has inherent advantages over gas chromatography, which 
are;
(1) A wide range of stationary and mobile phases . 
which improves the possibility of developing a selective 
and rapid procedure.
(2) The possibility exists for minimizing sample 
preparation time because:-
(i) Derivatization may not be required, and
(ii) Direct injection of urine and de-proteinated 
plasma may be possible.
(3) Operating at ambient or slightly higher temper­
atures means that thermally sensitive solutes are less 
likely to be decomposed during the analysis. In GC.,
the possibility exists for some decarboxylation of these 
non-steroidal anti-inflammatory ' agents to occur because 
of the high temperatures employed.
The developed procedure must be sufficiently sensi­
tive in order to be able to accurately quantify plasma 
and urine levels of the drugs and their metabolites.
This should be applicable both to the high doses en­
countered in chronic situations, and also to single dose 
studies encountered in bio-availability studies.
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The variable wavelength ultra-violet monitor would seem 
to be suitable for the detection of nanogram quantities 
of these compounds, and so meet these requirements.
The objective of this work was therefore to develop 
selective and rapid analytical HPLC procedures suitable 
for routine use in clinical situations. In this way, a 
contribution could be made towards the study of drug 
metabolism and availability in individual patients, with 
a view to improving the drug therapy they receive.
RESULTS AND  
Dl S C U S S I O N
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CHAPTER 4
The Development of HPLC Procedures
Silicagel has proved to be a highly successful 
material for the separation of non-ionic compounds both 
by thin-layer chromatography and by column chromatography. 
But the mechanism of. adsorption is less suitable for 
water-soluble and ionisable compounds. Liquid-liquid 
column chromatography employed partition as the reten­
tive mechanism, but suffered from the serious disadvantage 
of requiring the mobile phase to be saturated with the 
stationary phase. The development of chemically bonded 
phases has completely overcome this problem. The reversed 
phase material in particular has proved to be a remarkably 
versatile material, and has been the subject of many 
papers (46,4?). The reason for this versatility was not 
known at the start of these studies, although it was known 
that retention increased with increasing hydrocarbon chain 
length (48). With regard to selectivity, the approach 
adopted by most workers has. been the modification of the 
mobile phase to vary retention. Locke (49) proposed that 
the eluent order of solutes is the order of solute solubi­
lity in the mobile phase, i.e. decreasing polarity.
The retention mechanism of reversed phase chromato­
graphy then was that the hydrophobic surface attracts the 
more lipophilic component of the eluent to form an organic
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solvent rich layer at the hydrocarbon surface. The reten­
tion of various members within a class of compounds has 
been correlated to their solubility in the eluent. The 
early studies reported on the applications of reversed 
phase chromatography were:
(1) Ion pair partitioning chromatography of:-
(a) Biogenic amines and their metabolites (50)»
(b) Tricyclic psychosedative^ drugs (51)*
(2) Soap chromatography for the separation of ioni- 
zable materials (28).
Twitchett and Moffat in 1975 (52) evaluated the per­
formance of a reversed phase, (octadecylsilane, ODS), 
stationary phase for 30 compounds and found their chroma­
tographic behaviour to be predictable on the basis of pKa 
and partition coefficient. It was also found that the 
stationary phase was valuable for the separation of acidic 
and neutral drugs, but poor for basic drugs.
The versatility of the reversed phase material as 
demonstrated by the above workers led to its choice as a 
possible material for the analysis of anti-inflammatory 
agents based on their physicochemical properties, eg., pKa^
The profile study of these drugs shows that they are 
compounds of molecular weights between 200 and 400. They 
are structurally similar and classified as carboxylic and 
amidic or enolic acids. They are moderately lipophilic
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and weakly acidic, with pKa's between 4.5 and 7*5 and are 
extensively bound to plasma protein. These agents are 
partially soluble in water, readily in organic solvents 
and their solubility in aqueous medium is governed by pH 
(45). At pH 7*5» most of these compounds are expected to 
be significantly ionized, while at pH 3» negligible ioniz­
ation is expected (figure 4.1).
FIGURE 4.1
Ionization Process for the Acidic Protons In;-
(1) Carboxylic Acidst-




R-C-CH=CR ^R-C-CH^-C-R =^R-C-CH-C-R + H*^
II I ^—  II 2 II - —  |r~ T |
0 OH 0 0 O' '0
enol diketo enolate__
The choice of an .aqueous organic solvent might 
selectively solvate the solutes and result in their 
selective retention.
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4.1 The Initial Chromatogram.
Five of the anti-inflammatory agents were chosen to 
form a test mixture so that the selectivity of the chroma­
tographic conditions investigate&.jnight be assessed. This 
was considered to be important because it was hoped that 
the same basic method would be suitable for all of them.
It would also probably permit the analysis of any one of 
them in the presence of another anti-inflammatory agent.
Various aqueous acetonitrile mobile phases did not 
give a satisfactory separation. However, good resolution 
was achieved with aqueous methanol mixtures, especially 
between compositions of 30 to ^0% methanol. It was found 
that symmetrical peak shapes could be obtained for all 
the agents only when the pH of the solvent was adjusted 
to 3» figures4.2A*B.Analysis times were shortened and peak 
shapes improved by changing the column length from 200 to 
50mm., with equally good resolution.
The retention could therefore be explained in terms 
of solubility in the mobile phase with elution in order , 
of their decreasing polarity, i.e. most polar eluted first, 
The solubility is influenced by:-
(i) The of methanol in the mobile phase, and
(ii) The pH of the mobile phase.
The system is pH dependent because of its effect upon 
ionization of the solutes. In reversed phase chromatogra­
phy, when a dilute solution of ionizable solute is passed
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FIGURE 4»2A Separation of a Test Mix-ture
r- 2~
HPLC Conditions.
Column:- Spherisorb 5*0DS (50x4.6mm id) 
Mobile Phase - Methanol ; Water (45:55) pH-3 
Detector A, - 254nm







FIGURE 4.2B_ ■■Separation of the Same Mixture As in 4 .2A
ilS
HPLC Conditions,
Column : - Spherisorb 5-ODS (50x4.6mm Id) 
Mobile Phase - Methanol : Water pH ]. (35:65)
Detector X  - 254nm







through a hydrophobic organic stationary phase, the solute 
will be distributed between the two phases, figure 4.3.
A decrease in ionisation produces a decrease in the 
hydrophilic interactions with the aqueous mobile phase, 
thereby increasing retention on the hydrophobic stationary 
phase.
When pH = pKa-2, the ionisation of the solute is com­
pletely suppressed and the solute has a maximum capacity 
ratio. Under this condition of 'ionic suppression', the 
system is very selective for the solute, based upon its 
distribution between the hydrophobic stationary and hydro­
philic mobile phase.
The appreciation of these factors led to an investiga­
tion into their influence upon the retention of each of 
the drugs studied.
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FIGURE 4.3 Distribution of Solute HA.
Stationary phase: Hydrocarbon + adsorbed organic
modifier (MeOH)
HA
TT A A **HA V  ^ '==  A
Mobile phase: Aqueous Organic Solvent (H^ O + MeOH)
Equilibrium 1 is pH dependent and the degree of ionization 
is given by the Handerson-Hasselbalch equa­
tion, where
pH = pKa + log[|j]
Equilibrium 2 represents the distribution of the non­
ionised form HA.
The ratio of the concentration of the non-ionised 
form in each phase is a function of:
1. The pKa of the solute,
2. The pH of the aqueous phase, and
3. The distribution coefficient of the neutral, non­
ionised form between the stationary and mobile 
phases.
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4.2 The Effect of Organic Modifier Upon Retention and
Selectivity.
The effects upon retention for the ten anti-inflam­
matory agents are given in Table 4.1 and illustrated in 
Figure 4.4. It can be seen that, as expected, an increase 
in methanol concentration decreases the K' values for all 
the solutes. A change in elution order was observed only 
between the two compounds having the lowest K' values, 
namely, oxyphenbutazone and alclofenac. In general, no 
change in elution order occurred.
The selectivity of the conditions was measured by 
comparison of K' values for adjacent peaks at the various 
methanol concentrations. Selectivity is more informative 
when measured using a parent compound compared to a range 
of substituted derivatives. In this way, selectivity 
towards individual substituent groups is obtained. How­
ever, the series of compounds available here did not 
permit this treatment because of their differences in 
chemical structures. The data in Table 4.1 does show that 
for most adjacent peaks, selectivity is reduced as reten­
tion falls, as illustrated by the pairs (2,3), (4„5) and 
(6,7). It is also clear that selectivity towards all the 
compounds is good at methanol, and can be rapidly 
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4.3 Effect of-pH on Retention
At a constant eluent strength of methanol-water 
(50*50)» the effects of varying the pH of the eluent was 
observed on the'"retention of the agents (Table 4.2).
TABLE 4.2 Effect of pH on Capacity Ratios (K*)
K ’ Values at pH
Drugs 2.5 6.0 7.5
1. Oxyphenbutazone 1.33 0.50 0.10
2. Alclofenac 1.67 0.75 0.15
3. Ketoprofen 2.00 1.25 0.21
4 . Naproxen 2.33 1.38 0.28
5 • Fenoprofen 3.53 1.25 0.25
6. Phenylbutazone 4.00 2;13 0.43
7. Indomethacin 4.00 3.00 1.14
8 . Sulindac 5.67 3 i00 0.60
9. Diflunisal 6.00 2.00 0.40
10. Benoxaprofen 9.00 7'.36 1.68
Column: Spherisorb 5“ODS 
(50x4.6mm id)
Mobile Phase: Methanol:Phosphate Buffer
(50:50)
Detection: 254nm
The results are further illustrated in figure 4.5.
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pH of Mobile Phase
6 0
Usually, the ionic solutes are not absorbed at all 
by the non-polar stationary phase, because highly polar 
or ionic solutes interact strongly with the aqueous sol­
vent and are easily solvated (30B) .
From the graph, there is a marked decrease in the 
retention of the drugs when the pH rises above 3 where 
ionization of the solutes begins and the order of reten­
tion is changed. When this occurs, K' values are gener­
ally less than 3» which is too small for analytical 
studies in the presence of biological fluids. It is 
apparent therefore that no improvement in selectivity can 
be obtained by choosing a pH at which ionization of the 
compounds occurs, and that retention is more conveniently 
controlled by changing the methanol concentration. Ioni­
zation of the solutes causes the solutes to interact 
strongly with the aqueous mobile phase and are thus easily 
solvated. This makes the solutes less retained.
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4.4 Ion-Pair Chromatography.
An alternative approach to the enhancement of reten­
tion of ionizable compounds is to use ion-pair chromato­
graphy. This technique involves the addition of an 
oppositely charged pairing-ion to the chromatographic 
system, so that solute retention is effected by ion-pairing 
by various mechanisms^ Schill, Persson and co-workers (53- 
55) pioneered this technique for normal phase chromatogra­
phy, in which the pairing ion is loaded on to a hydro­
philic. stationary phase such as silica gel. In a recent 
application of this technique, Schill (5&) used perchlorate 
as the pairing ion and separated two amines, zimelidine 
and demethylzimelidine from plasma using methylene chloride 
and n-butanol as mobile phase. However, solutes must be 
dissolved in the mobile phase before injection, and meti­
culous thermostatting of the chromatographic system is 
necessary for column stability. The method has been used 
by other workers such as Persson and Karger (50) for bio­
genic amines, and Knox and Jurand (51) for tricyclic 
tranquilizers. It is also an excellent method for solutes 
having little or no UV absorbance.
In 1975» Wittmer, et al. (57) used a reversed phase 
column with a mobile phase of aqueous methanol containing 
tetrabutylammonium hydroxide* as"pairing ion. This en­
abled a very polar sulphonic acid dye tartrazine, and its
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intermediates, to be adequately retained for good resolu­
tion. In 1976, Knox and Laird (28) introduced "Soap 
Chromatography" to describe their studies using cetyltri- 
methylammonium bromide (cetrimide) as a pairing ion in 
both reversed phase and silica gel columns. The solutes 
examined were also a range of sulphonic acid dyestuffs, 
which had given tailing peak shapes using conventional 
adsorption or normal phase ion-pair chromatography using 
tetraalkylammonium pairing ions. This was attributed to 
the very strong polarity of the —SCy— group displacing 
water from the silanol sites on the silica surface, even 
in the presence of a strongly aqueous mobile or stationary 
phase. However, they found that highly efficient columns 
were obtained (h A 2x particle diameter) in the presence 
of cetrimide for both reversed phase and silica gel 
columns, which is comparable to that obtainable in normal 
adsorption c^omatography. In the reversed phase mode, 
the retention mechanism was considered to be probably a 
combination of two mechanisms:-
(1) Formation of the cetrimide-sulphonate ion-pair 
in the mobile phase, followed by distribution into the 
hydrophobic stationary phase.
(2) Ion-pair formation between cetrimide adsorbed 
into the hydrophobic stationary phase and sulphonate ions 
in the mobile phase.
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From the many papers published since 1976 on this 
topic and recently reviewed (58)» it would seem probable 
that both mechanisms frequently occur simultaneously, and 
that the percentage of organic modifier is a key factor in 
determining which retention mechanism will dominate (29).
In spite of the detailed studies of Horvath and co-workers 
(30B), the various equations describing the equilibria 
involved when used with experimental data are unable
to distinguish between the two mechanisms.
In view of the excellent column efficiencies obtained 
with cetrimide, it was decided to investigate the suita­
bility of this pairing-ion for non-steroidal anti-inflam­
matory agents. The results are tabulated in Table 4.4 
and illustrated in figure 4.6. Although the pH of 7*5 was 
not sufficiently high to ensure complete ionisation of all 
the drugs studied, it was used because it was the highest 
value recommended for silica-gel.
It was found that K' values increased rapidly in the 
presence of cetrimide, and were excessively so .(>10) for 
the most hydrophobic agents, namely sulindac, indomethacin, 
diflunisal and benoxaprofen. For the other agents, at a 
pairing ion concentration of 2 x 10~^M, K' values were 
generally more than doubled with little change in selec­
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Concentration of Cetrimide in the Mobile Phase
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Figure 4.6 illustrates that the relationship between 
retention and pairing-ion concentration is typically sig­
moidal, as has been shown by other workers (59)» This is 
thought to be due to the depletion of the pairing-ion by 
the solute at very low concentrations. Thus the optimum: ' 
pairing-ion concentration to use would be 1.5 to 4 x lO^^M,
i.e. the rising portion of the curve. The elution order 
of the compounds was not altered by variations in pairing- 
ion concentration, which is in agreement with the work of 
Johansson, et al. (60).
The formation of the ion-pair may be described by the 
equation:
+ RCOO'H*
cetrimide 1  anti-inflammatory acid
ion pair
The equilibria involved in the mechanisms of reten­
tion by reversed phase ion-pair chromatography have been 
described by Horvath and co-workers (30B) as
E + H ^ ^  EH - ^ E+ H , mobile phase
r K
K4 K3
LE + H %--& LEH ^   ^ E+ LH stationary phase
where E = solute = anti-inflammatory acid 
H = pairing-ion 
L = hydrocarbon surface.
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The two retention mechanisms may be represented by 
the equilibria:-
(a) KgKji^ = Ion-pair formation in the mobile phase
followed by transfer to the stationary 
phase, and
(b) = Ion-pair formation between adsorbed pair­
ing ion and anti-inflammatory agent in 
the mobile phase, also known as in-situ 
ion exchange.
When control plasma and urine samples were injected 
into the cetrimide system, it was found that the elution 
volume required for the peaks to elute was much increased 
because these materials normally contain endogenous acidic 
compounds capable of forming ion-pairs with the cetrimide, 
so increasing their retention, when compared with those 
obtained using ionic suppression.
Another feature of the ion-pair system was that at 
pH 7*5» the anti-inflammatory agents exhibited a lower 
absorbance in UV light so that sensitivity of detection 
was impaired.
In view of results obtained with cetrimide, it was 




4.5.1 Significant Features of the HPLC Technique.
The HPLC procedures developed and used in these
studies have been based upon reversed phase chromatography 
utilizing ionic suppression of the solute. The column 
capacity ratio of a solute is a measure of the balance 
between retention caused by hydrophobic interactions of 
the solute-stationary phase complex and elution caused by 
interactions between solute functional groups and organic 
modifier. Thie is capable of producing a wide range of 






The inherent advantages and applicability of this 
method can be examined by comparison with gas chromato­
graphy and thin-layer chromatography. Thin-layer chroma­
tography offers several advantages over HPLC in that : -
(i) The technique is simple and inexpensive,
(ii) A number of samples can be separated simultane­
ously on the same layer.
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(ill) The separation can be carried out in two dimen­
sions with two different eluents, and
(iv) No components are overlooked, since the sample 
is detected on the chromatographic system.
However, the:disadvantages are ; -
(i) The precision of quantitative analysis is moder­
ate,
(ii) The precision of the migration data for identi­
fication is moderate,
(iii) The method is not favourable for automation,
and
(iv) The number of theoretical plates is limited by 
the fact that the fluid velocity decreases to zero with 
time.
Gas chromatography also has some advantages over 
liquid chromatography in that : -
(i) In general, for solutes having a K' value greater 
than about 10 or 20, G.C. produces better peak shapes than 
HPLC.
(ii) Extremely high plate numbers may be obtained 
using capillary columns.
(iii) Detectors in GC are much more sensitive. The 
flame ionization detector, FID, available in GC is very 
sensitive, with a detection limit of about 10“ g^m, i.e. in 
the ng range, and responds to almost all organic compounds.
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The electron capture detector is about 100 ,: times more 
sensitive to halogenated compounds or derivatives. For 
HPLC the UV variable wavelength detector is suitable for 
organic compounds having -conjugated double bonds, and is 
sensitive in the ng range. Fluorimetry is also available 
with at least a xlO improvement in sensitivity.
But on the other hand, HPLC offers several distinct 
advantages over GC, including:-
(i) The ability to analyse material of veiy low 
vapour pressure without the preparation of volatile deri­
vatives,
(ii) Analyses of thermally unstable materials may be 
accomplished with ease, since the technique can be operated 
at room temperature.
(iii) The polarity of the mobile phase compared with 
stationary phase is readily variable to provide a wide 
range of different conditions capable of achieving a 
separation.
The method of reversed phase chromatography using 
hydrocarbonaceous stationary phases with hydro-organic 
solvent mixtures has proved to be extremely versatile, and 
probably accounts for 60-80^ of all applications published 
recently. The features of reversed phase HPLC responsible 
for its flexibility include:-
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I. - An aqueous mobile phase which •provides;
1. Compatibility with biological fluids, since most 
biomolecules are compatible with such an environment, 
solubility can be readily achieved.
2. Operational simplicity by the use of aqueous 
organic solvents, thus avoiding dangerous and toxic sol­
vents .
3. Selective equilibria such as ionization (61,62), 
ion pair (55,58), and ligand exchange (63) may be employed, 
creating special opportunities for ionizable substances.
However, the presence of water is a major disadvan­
tage when HPLC- is linked to Mass Spectrometry. Analyses 
have been achieved on HPLC-MS using a mobile phase contain­
ing not more than 40^ water (64).
4. Good column stability,
(a) Water or biological fluids in the injection 
solvent will not influence retention because water is 
already present in the mobile phase. In contrast, traces 
of water in the injection solvent will cause retention 
variations with silica gel columns, as used in adsorption 
chromatography.
(b) Highly polar impurities or metabolites fre­
quently elute unretained, whereas they accumulate in 
adsorption chromatography and are retained on the column, 
gradually degrading its performance.
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II. Weak surface energies of bonded alkyl phase.
This permits not only rapid analyses but rapid equili­
brium when eluents are altered. About 10-25 column volumes 
were necessary for equilibrium to be reached on reversed 
phases, whereas about 50-100 or more are required for 
silica. For the same reason, not only aqueous solutions,
I
but protein or particle free biological fluids can be 
injected directly into reversed phase columns.
III. Application to Physico-chemical Studies.
Reversed phase systems have also been used as a
physico-chemical tool for characterization of biochemical 
substances, eg., comparing fundamental properties of mole­
cules' and their metabolites for their hydrophobicity (65) 
(Chapter 5)•
^  The current limitations in reversed phase HPLC are:-
(1) Stable columns can be obtained only between 
the pH range of 2 to 7»5* At low pH, attack of the Si-C- 
hydrocarbon bond is possible whereas at high pH, the 
siloxane structure of silica may be attacked, particularly 
in salt solutions. Most of the analyses in this work were 
achieved at pH of between 2.5 and 3» and columns were 
found to be stable and with good performance for over six 
months. However, regular regeneration of columns with 
methanol was necessary.
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(2) The remaining silanol groups (Si-OH) on the 
silica surface, figure 2.7» often influence the retention 
of polar, and particularly basic compounds. If these 
silanol groups are accessible for interaction, then reten­
tion will be affected and peak tailing may result.
(3) The variety and quality of commercially avail­
able reversed phase materials have lacked uniform perfor­
mance, although the order of elution is usually identical 
under the same conditions, figure 7.6,
4.5.3 Load Capacity.
Unlike gas chromatography, HPLC can be used for semi­
preparative separations without instrument modification.
It means that a peak of interest may be collected, from a 
number of injections and then subjected to further study. 
For example, ketoprofen glucuronide (Chapter 5) was col­
lected, hydrolysed, and the presence of ketoprofen con­
firmed by HPLC. For preparative studies, columns of wider 
internal diameter (8mm.id.) and longer lengths (200-300mm) 
are often used.
4.5.4 Selectivity.
This is the intrinsic capability to distinguish 
between two components. The separating power of reversed 
phase system arises from:
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(i) The control of mobile phase, and
(ii) The performance of the column.
(i) Control of Mobile Phase:-
The effect of solvent strength for all the samples 
was always investigated as demonstrated earlier in this 
chapter (2.1.2.2) before the optimum eluent strength was 
logically chosen. This is because solvent strength is 
the sum total of three types of intermolecular inter­
actions acting concurrently, eg., dispersion, orientation 
and hydrogen bonding (66). Each solvent has these inter­
active "components in a unique ratio. Thus, two solvents 
of approximately equal polarity can have different inter­
active profiles. Solutes also have a profile, and when 
there is a good interactive match between solvent and 
solute, the solvent strength is particularly high. Selec­
tivity is thus the degree to which a solvent is chromato- 
graphically stronger for a particular solute by virtue of 
its ability to enter into specific intermolecular inter­
actions to a greater degree than for other solutes.
Reversed phase systems in these studies have used 
water as a mobile phase component. It is a unique solvent 
with a high cohesive energy density which produces a high 
surface tension. All but the most polar or ionic solutes 
experience a hydrophobic force that drives them onto the 
stationary phase and causes retention (6?). The hydropho­
bic effect results from the strong attractive forces
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between water molecules. Highly polar or ionic solutes 
can themselves interact strongly with water and are thus 
easily solvated, but non-polar solutes are relatively 
insoluble.
The solute is retained in the hydrophobic stationary 
phase coated by a monolayer of the organic modifier, 
figure 2.8. The hydrophobic force of water isusually 
reduced by adding miscible organic solvent. Methanol has 
proved to be the solvent of choice in these studies largely 
because its polarity renders it a good solvent for acidic 
anti-inflammatory agents. It is stable with a low vis­
cosity, and does not present a serious health risk to the 
user.
Thus, the technique of HPLC is ideal for the analysis 
of acidic anti-inflammatory agents either alone or in com­




Applications of HPLC Procedures Developed.
The preliminary studies had provided two chromato­
graphic systems, namely ionic suppression and reversed 
phase ion-pair chromatography that could be used in the 
analysis of these anti-inflammatory agents. The choice 
between the two has been based on:-
(i) The ability to control the ionization of the 
solutes at the selected pH;
(ii) The stability of the drugs at the working pH 
over a fairly long period of time;
(iii) The sensitivity or the coefficient of extinc­
tion of the agents in UV light at the chosen pH - to aid 
detection;
(iv) The ease of sample preparation which controls 
the use of solvents and also the cost; and
(v) The analysis time, since efficient assay proce­
dures aimed for routine work should have a short analysis 
time.
The advantages of using ionic suppression for the 
chromatographic conditions were considered to be:-
(i) Diluted control urine and deproteinated plasma 
was largely unretained and did not produce any peaks 
likely to interfere with the solutes of interest. This
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enabled K* values between 4 and 10 to be chosen for the 
solutes, thus ensuring that analytical times would be 
short.
(ii) At a pH of 31 the ionization of all the drugs 
was adequately suppressed to provide a variation of K' 
values based upon their relative hydrophobhcities.
(iii) Symmetrical., narrow peaks were obtainable, 
suitable for quantification by peak height measurement.
(iv) The drugs and column material were known to be 
stable at pH 3» Clinical samples are also preserved in 
acid medium prior to their analysis.
(v) The drugs have higher molar extinction coeffic­
ients in acid conditions than in neutral or weakly alka­
line solvents, thus increasing their sensitivity to detec­
tion by UV monitors.
Karger in 1978 (68) from his previous studies and 
experience has also found it sometimes preferable to 
chromatograph a solute in its non-ionized form since there 
is then less chance of secondary equilibria influencing 
retention or band shape.
Ionic suppression mechanism on a reversed phase 
column using aqueous methanol at pH 3 has thus been chosen 
for the study of these drugs in biological fluids. In 
this system, more polar metabolites and impurities elute 
before the drug. By choosing a capacity factor K' of 
between 4 and 10 for the drug should clearly separate the 
biological fluid components and drug metabolites from the 
free drug.
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5.1 Determination of 10 Non-Steroidal Anti-Inflammatory 
Agents in Plasma and Urine.
5.1.1 Sample Preparation:-
The schematic representation of the procedure is 
shown in figure 5*1A and B which involves extraction of 
the free drug from acidified aqueous plasma or urine into 
the organic solvent, diethylether.
5.1.2 Assay Procedure:-
2.1 HPLC Conditions >
The summary of the HPLCT conditions which include the 
mobile phase composition, the detector wavelength, the 
internal standard used and the limit detected for each 
drug is shown in Table 5»1»
2.2 Calibration of Drugs in the Mobile Phase.
Drug concentrations in the range of 1.0 to 80jüg/ml
in the mobile phase were prepared by suitable dilutions 
of the stock solution of the drug (Img/ml) in the mobile 
phase. Calibration plot of the peak height ratio of the 
drug to the internal standard vs the concentration of the 





























































































— 7^ tH tH NO tH O O CA VA>s m ^  - . • . ■ • •
ü cd *H +|o tH CM ON tH CM CA CA
C § g
•H cd iH . u> tH NO ON 00 00 tH 00 £>- NO
ü rH cd ü tH • • • • • • ■ ■ • .•H Ph c 0) O NO JN- tH tH CM OO CM
q-t C ^  C O ON O O O O O O ON O4-1Pr1 tH tH tH tH tH t—1 tH tH
' U
c; 4h cd vn o- VA 00 tH OO CM OO
o <+H >
•H CQ c ^ cq tH CM tH tH VA CA■P •H^  04h
ü Q) m+ lo o
03 C >U •H iH • o\ CA tH O- O o
-P Cd Ü'O 00 O . tH tH tH NO VA OO • OnX 5  C 0 tH '# • • • . • e ■ «
M C 0=; _ ON [>- tH ON tH tH CM O Oc ON ON O ON O O O O o O
tH tH tH tH tH tH tH
0
d 0
o dN d o dr-f nO 0 •H ISl •H
Cd P-, d d ■P ü 0 ü
C Cd 0 0 d 0 ■P 0Li T3 4h «H Xî X: d d d X
0 c: O O d -p 0 X 0 X-p 0 d d 0 0 % X X 0Ü-H A A . Æ g o >s G sH  U2 O O A G d d d G■P •P >s •G A 0 A 030 0 % d 0 X 0 d
W X O M S Ph S M
o ti£
•H C O O O
■P^ o o VA O O VA O VA VAü -P • • ■ ■ ■ . . • • ■
0 .H vn o CM CM VA CM CM VA CM CM




0 o d 00 O VA CM 00 O O
-=h o- NO C^ VA OO NO VA O0 +3 CNJ CN2 CM CM CM CM CM CM CM CAQ'.
m
0 NO O £N- O O VA CA VA CA
£>- ON CM VA -:j' CM CA CM CAX  iH





VA VA VA VA •VA VA O O





O dN O d d
0 eq •H 0ra -P ü d d 0 ü A X-p d 0 0 0 -P 0 0 G
d s tH d «H d ü X ra d0 d 0 O 0 O X 0 X •H A0 4h d % d A nd 0 d 0< X: o A O A d B d %A rH o d O d •H O rH GK ü ■P A d 0 A Tl 4h d% 1—1 0 0 0 X d d •H 0o <!. X s A Ph OQ H Q pq
tH CN2 CA VA NO C^ 00 ON otH
82
5.1.2.3 ; Evaluation of Extraction Efficiency from Plasma 
and Urine.
Drug and internal standard were added to control 
plasma or urine to produce a series of solutions contain­
ing 1.0 to 8Qug/ml of drug. The solutions were then 
extracted as described in figure 5.1A and B, chromato­
graphed and the results compared with calibrations ob­
tained using mobile phase only, to give the extraction 
efficiency, Table 5.1.
The slopes of the calibrations may also be used to 
provide a ^ recovery, such that
% Recovery =
Calculated Slope of Solute Concentra­
tion Extracted from Plasma or Urine
Calculated Slope of Solute Concentra­
tion in the Mobile Phase
X 100
(See Appendix 1.)
With either method, the percentage recovery rates 
have been found to be greater than 95^ for each drug. The 
assay procedures from urine without extraction and from 
plasma supernatant were found to be very reproducible. 
Extraction might be needed in order to improve the life and 
efficiency of the column when used routinely, but when the 
solute concentrations are expected to be low, direct injec­
tion is advised.
Some of the typical calibration plots and chromato­
grams of the assay obtained from agents in plasma and 
urine are illustrated in figures 5*2 to 5«S»
mQ
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1. This procedure can be used to determine these 
drugs in other biological fluids. The recovery of 
the drugs from "spiked" milk and saliva had also been 
obtained, although of low practical clinical significance*
2* Clinically:-
(i) These drugs are administered chronically and 
because they are weak acids, their main side effect is 
gastric ulceration which can impair absorption of the 
drug. This can be checked by monitoring blood levels,
which also provides a check on patient compliance.
(ii) Most of these drugs are excreted largely as 
their glucuronide conjugates. The conjugated drug is 
usually analysed by first converting the conjugate back to 
free drug by hydrolysis to provide a measure of the total 
drug excreted in the urine. Hydrolysis was achieved 
by (figure 5.6) either
(a) addition of ^ml of 6NHC1 to 5ml of urine and 
refluxing for about 30 mins.-provided the drug is stâble, or
(b) incubating 2ml of urine adjusted to pH ?.5 with 
phosphate buffer, with 1ml of ^-glucuronidase enzyme at 
37°C for at least 18 hours.
The glucuronide conjugates of these drugs elute at 
the solvent front because they are very polar making it 










































attempt to analyse the glucuronide 'conjugates of ketopro- 
fen and benoxaprofen to establish a procedure for these 
drug conjugates is described in Chapter 5«3«
(iii) This chromatographic method also provides a 
routine procedure for the study of future drugs in this 
group in body fluids. It has been directly employed for 
the study and clinical trial of a novel anti-inflammatory 
agent, benoxaprofen, conducted at Royal National Hospital 
for Rheumatic Diseases in Bath. The results, from the 
study of 10 patients on a steady dose of 600mg of benoxa­
profen per day,sta6wedan average plasma level of 120 + 3Zug/ml 
(figure 5»7A and B).
Stability of the Drugs.
The drugs have been found to be stable when stored 
for over a month at about 5°C. in acidified methanol-water 
or in acidified plasma or urine when stored frozen at about
Analysis Time.
The analytical procedure is rapid to perform,"one 
single extraction is usually required before chromatogra­
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5.2 Drugs and Their Metabolites in Body-Fluids.
The study of drug metabolites is important in clini­
cal chemistry because it:-
(i) Provides more information about the nature of the 
parent drug,
(ii) Explains the duration of action of the drug, and
(iii) Shows the excreted forms of the drug.
The pharmacological activity of drug metabolites is 
generally different from that of the parent drug, so that 
the fate of the drug and the rate at which bio-transforma­
tion occurs is an important clinical consideration. This 
is especially so for drugs taken over long periods, and 
also in the examination of patients suffering from an 
overdose. It is of special value in Forensic Analysis 
where there might be total absence of the parent drug due 
to biotransformation, so that the correct separation and 
identification of the metabolites found in body fluids 
would thus lead to the confirmation of the identity of the 
drug.
Factors to be taken into consideration while develop­
ing the method, include high sensitivity and selectivity, 
ease of sample preparation and the analysis time.
Small quantities of some of the metabolites of indo­
me thacin, naproxen, phenylbutazone and sulindac were ob­
tained from the sources listed in Table 7.1 and so per­
mitted a chromatographic study of these drugs.
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Pound, et al. (24,25) have described methods for the 
simultaneous determination of phenylbutazone and oxyphen- 
butazone which have been discussed in Chapter 1.4. Very 
recently, Wan and Matin (69) described a GLC method invol­
ving butylation which differentiated between naproxen and 
its 6-desmethyl metabolite and were quantified simultane­
ously in urine. No other HPLC procedures have been des­
cribed for any of these drugs with their metabolites.
Reversed phase chromatography with aqueous acidic 
methanol was chosen because the metabolites are usually 
more polar than the parent drug and so elute sooner.
Total analysis time was therefore defineable, and the 
retention range available for the metabolites was limited. 
This is a major advantage over the HPLC method described 
by Pound (25). In the absence of standards, this was also 
an advantage because it offered the ability to determine 
the end of the analysis and to suspect any major peak 
eluting before the parent compound as the metabolite.
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$.2.1 Effect of Changing: Eluent Strength on the
Capacity Factor (K') and the Selectivity (ot) 
of Drugs and their Metabolites.
In order to determine the optimum composition of the 
mobile phase for the four drugs and their metabolites, 
the effect of adjusting the methanol composition on reten­
tion and selectivity was studied, using the conditions 
previously described for ionic suppression. The,results 
are expressed in Table $.2 and illustrated in figures 
5,8 A-D, Chromatograms of:-
(i) Analysis of indomethacin and its metabolites 
using phenylbutazone as the internal standard, fig. 5*9 
and
(ii) Analysis of naproxen and its metabolite with 
oxyphenbutazone.as the internal standard, fig. 5»iO*
There was a good correlation between the elution 
order of the drugs and their metabolites and their rela­
tive hydrophobicities, as predicted. Also, the relation­
ship between the log methanol concentration of the mobile 
phase and log of the drugs and their metabolites from 
Table 5*2 produced correlation coefficients of between 
0.96 and 0.999. The separation obtained produced reliable 
quantification in a reasonable analysis time.
The results clearly show that good separations are 
possible for these drugs and their metabolites. The 
differences observed in the Yi^ values between drug and 
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Spherisorb 5-ODS. (50x4.6nin id.) 
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(1) the loss of a methoxy [-OCH^]group and a gain of 
a [-OH] group in naproxen and indomethacin to give more
polar desmethyInaproxen and desmethylindomethacin;respect­
ively.
(2) the hydroxylaf ion of one phenyl group of phenylbut­
azone to form a more polar oxyphenbutazone.
(3) the loss of chlorobenzoyl group in indomethacin 
to form a more polar deschlorobenzoyl indomethacin, and
(4) the metabolism of sulphoxide to produce a more 
polar sulphone derivative of sulindac.
The reversed phase system has thus permitted these 
polar metabolites to elute before the parent drugs 
whereas they are longer retained in adsorption chromatog­
raphy or accumulate on the column, gradually degrading its 
performance.
5.2.2 Determination of Sulindac and its Sulphone and 
Sulphide Metabolites in Plasma and Urine
One exception to the general rule that metabolites' 
are less hydrophobic than the parent drug, is provided 
by the sulphide metabolite of sulindac. As a consequence 
this metabolite is excessively retained, leading to a 
reduced peak size and sensitivity of detection, making the 
method unsuitable for quantitative analysis.
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This problem was solved by using an amino-bonded 
phase, that possesses the polar functionaiL group NH2 
bonded to the hydrocarbon chain. This makes the phase 
less hydrophobic than the octadecyl phase and so shortens 
retention due to hydrophobic interactions^ ^
Optimum retention of sulindac and its metabolites 
on this column is brought about by careful changes in the 
isopropanol-acetic acid content of the mobile phase. 
Decrease in acetonitriLe content of the eluent brings 
about early elution of the compounds while increase 
causes retention.
5.2.2.1 Assay Procedure.
The chromatographic condition was set up with the 
filtered mobile phase to establish a steady base line on 
the recorder.
To 1ml of plasma in a 10ml glass centrifuge bottle,
1ml of conc. HCl was added to precipitate the proteins, 
then the drug and its metabolites were extracted in ^ml




Calibration samples were prepared by measuring 3Dnl 
of suitable sulindac, sulphone and s'ulphide solutions into 
5ml tubes of plasma or urine each with 500ng naproxen, as
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internal standard to make 5 samples containing 4, 8, 12,
16 and 2Qug/ml respectively of the compounds, (figure 5*10)
5.2.2.2 Results.
Calibration graphs of peak height ratios of sulindac 
to naproxen vs. sulindac concentration; sulphonè to napro­
xen vs. sulphone concentration; and sulphide to naproxen 
vs.sulphide concentration were constructed. The graphs 
were straight lines passing through the origin (with cor­
relation coefficient 0.999) (Figure 3 .11 )
Ren ro due ib i1i ty.
Samples of spiked urine and plasma from healthy humans were 
analysed. Table 5«3 shows that this procedure permits 
the quantitative assay of sulindac and its metabolites 
down to 4Mg/ml, though when a higher sensitivity is re­
quired, larger sample volume, eg. 251 50 or lOOjjl of the 
extract, could be injected. The absolute detectable con­
centration was 2.5ng. at 0.2AUFS. The yields Coeffic­
ient of variation of extraction from plasma or urine are
95 j+6.0^ for Sulindac,
99 ±8^ for Sulphide (n = 1?)
98 ±6% for sulphone.
The metabolites were found to be stable in the solu­
tion of the mobile phase at pH 2.5» No decrease in the 
drug and its metabolites was observed in plasma and urine 
when stored frozen for a month.
10 3
FIGURE- 5»'1~0. Assay of Sulindac and Its Metabolites in 
Plasma.
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TABLE 5.3 • Reproducibility and Accuracy of the Assay of 
Sulindac and Its Metabolites in Human Plasma 
and Urine.























Sulphide Plasma 4 99.27 0.75
8 95.75 4.89
12 97.11 - 1.77
16 103.65 0.26
20 101.45 2.68
















Sulindac and its metabolites provide an interesting 
variation in the *study of drugs and their metabolites. 
Compared to sulindac, the sulphide metabolite has a longer 
half-life in plasma, and possesses a more potent anti­
inflammatory property. Figure 5«12 shows the profile of 
suilindac and its metabolites in the plasma of a healthy 
volunteer following an oral dose of 200mg of &ulindac.
In urine, the sulphone is the major form together with 
a small amount of free drug.
The sulphide is also more lipophilic than s-ulindac 
which means that it will have a larger K'value when chro­
matographed :on a reversed phase column. Typical K'values 
were 3.0, 4.0 and 22.3 obtained for sulphone, sulindac and 
sulphide respectively (figure 5*80).
Further works carried out on the amino-bonded silica 
material revealed that the stationary phase could be em­
ployed also for the separation of naproxen and desmethyl- 
naproxen. It is not suitable for indomethacin and its 
metabolites because indomethacin and deschlorobenzoyl- 
indomethacin could not be sufficiently-well resolved for 
accurate analysis.
The amino-bonded stationary phase has been applied 
to analyze the plasma and urine samples collected from 
a patient during a change over period between sulindac 
and naproxen therapy (figure 5»13A and B). The
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FIGITRE 4.12 Profile Study of Concentrations of Sulindac 
and Its Metabolites in Plasma of a Healthy







FIGURE' ^ .13 - Clinical Samples of a Patient Receiving 
Clinoril (Sulindac) and Naproxen Drugs.
Time in mins
A - Sample of Clinical Urine
B - Sample of Clinical Plasma
1 - Organic Solvent Front
2 - Naproxen
3 - Sulphide 
^ - Sulphone
5 - Desmethylnaproxen
6 - Sulindac -. .
Column - Spherisorb - ^NHg 
(250x4,6mm id)
Mobile Phase 




chromatograms obtained illustrate that the metabolites are 
all resolved, and show the absence of desmethylnaproxen in 
the clinical plasma sample with the presence of desmethyl­
naproxen and absence of sulphide metabolite in the urine 
sample.
The same single extraction procedures described in Chap­
ter 5*1 have been employed and the % recovery has been • 
greater than 98^ +4^ coefficient of variation for the drugs 
and their metabolites. (See Appendix.)
The amino bonded phase packing material is newly 
introduced and recommended by the manufacturers for polar 
solutes. -It is employed here in a form of straight 
phase chromatography (figure 2.6). It is weakly polar; 
the mobile phase is non-aqueous and acidic. The mechanism 
of retention is a mixture of hydrogen-bonding and hydro- 
phobic interactions. The hydrogen-bonding will also occur 
with the isopropanol in the mobile phase, therefore an 
increase in the percentage of isopropanol will decrease 
retention.
The differences observed in the K* values between the 
drug and its metabolite are due to changes in drug polarity,
eg., naproxen  ►desmethylnaproxen, a loss of methoxy
(-OCH^) and again of -OH which has conferred high polarity 
necessary for its excretion. The higher K’ value for des­
methylnaproxen, figure 5«13» further shows that the reten­
tion mechanism is predominantly due to polar interactions 
in the stationary phase.
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The major disadvantage in the use of an amino-bonded 
silica column is the inability to inject the biological 
fluid directly onto the column. The compounds first have 
to be extracted into a suitable organic solvent such as 
ether (figure 5-lA and B). The sensitivity obtained using 
this column has been found to be considerably higher than 
using a reversed phase column.
5.2.3.A Comparison of the metabolism of naproxen under 
different biological conditions.
The study of drug metabolites has been achieved using 
four different methods:-
(1) Animal liver homogenate preparation,
(2) Dosing healthy rabbits,
(3) From healthy human volunteers given the drugs, and
(4) From clinical samples obtained from patients who 
were being treated with these drugs.
The first two methods were carried out in the school 
while three and four were carried out in the ".Royal National 
Hospital for Rheumatic Diseases, Bath.
The liver homogenate was prepared by slight modifi­
cations of the published methods. (95) The incubation 
was carried out in unstoppered conical flasks at 37 C^. for 
at least 3 hours. Each incubate contained-
Ill
(a) Substrate - the drug 7mg/ml in water - 1ml
(b) Liver homogenate Igm/ml - 2mls
(c) Ice-cold phosphate buffer pH 7*5 - 3mis
(d) Co-factor solution - 1ml
Total volume per flask - 7mls
The 1ml of the cofactor solution consisted of:-
(a) Glucose-6-phosphate sodium (20ojmoles) 6.0mg
(b) Nicotinamide adenine diphosphate - 
disodium salt NaDPNag (4jumoles) 3»4mg
(c) Magne slum chloride sol. (MgCl^) (O.IM) 0.2ml
(d) Distilled water
Three sets of experiments were carried out concur­
rently .
(A) Control homogenate incubate, i.e. no substrate 
added.
(B) Homogenate incubate with substrate.
(C) Homogenate incubate with substrate and 2mls of 
^-glucuronidase enzyme.
The incubation reactions were terminated by cooling 
the flasks in ice and either protein-free supernatant or 
extracted compounds from the incubate were injected direc­
tly onto the column;..
The chromatograms on figures 5*14 show typical 
results obtained using naproxen as the substrate. The 
chromatographic conditions described in figure 5*10 were







H - Homogenate peak.
Injection of homogenate incubate with naproxen 
DN - Desmethylnaproxen 
N - Naproxen
Injection of homogenate incubate with naproxen and 
^-glucuronidase enzyme.
H - Homogenate peak.
DN - Desmethyl naproxen.
N - Naproxen.








Injection of c-ontrol naproxen 
N - Naproxen
Injection of control desmethyl naproxen.
DN - Desmethylnaproxen.
Injection of clinical urine sample of naproxen.
U - Urine peak.
DN - Desmethylnaproxen.
N - Naproxen.
Injection of hydrolysed clinical urine sample of naproxen.




employed. It is interesting to observe the similarities 
between the result obtained with the liver homogenate and 
that from clinical urine sample, figure 5«i5» It shows:-
(i) Increase in naproxen and desmethylnaproxen after
hydrolysis, therefore indicating both are present as
 ......................................
hydrolysable conjugates.
(ii) The same pattern occurs in clinical urine and in 
animal liver homogenate, supporting the general^view that 
conjugation occurs in the liver before excretion of the 
conjugated glucuronides by the kidneys.
(iii)It illustrates the usefulness of employing animal 
liver homogenates to study metabolism of drugs.
(iv) Neither the homogenate, nor clinical urine con­
tained sufficiently high levels of metabolites to enable a 
semi-preparative separation to be worthwhile, indicating 
the need for dosing healthy animals.
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5.3 The Analysis of Drugs and Their Glucuronide Conju­
gates in Biological Fluids.
Most of the anti-inflammatory agents studies here 
undergo conjugation.with glucuronic acid to be excreted 
as the glucuronide. Apart from the technique of radio­
immunoassay, the glucuronides have not received much 
attention analytically. The most common procedure for 
their estimation is by measuring the difference in the 
value for the free drug before and after hydrolysis. It 
was felt that HPLC should permit the separation of glu­
curonide from the free drug and so make it possible to 
analyze them directly.
However, no glucuronides of these anti-inflammatory 
acids were available commercially, or could be synthesized. 
The most efficient method of conjugating a drug is to use 
a laboratory animal such as the rabbit, and this was used 
later, but an analytical technique was first required that 
could be used to identify the extracted glucuronides.
For this purpose, a range of commercially available 
glucuronides listed in figure 5 .I6 and purchased from 
KOCH-LIGHT Laboratories Ltd., (Buckinghamshire, England), 
were used to investigate possible HPLC systems for anti­
inflammatory drug glucuronides. Reversed phase chromato­


































5.3.1 Effect of Eluent Strength on the Capacity Factor 
(K*) and Separation of Aglycones and Their Glu­
curonides .
Glucuronides are weak acids and they largely account 
for the excreted forms of most of the arylacetic acids.
The chromatography could then be treated as described in 
Chapter 4 either by suppressing ionization of the glucu­
ronides or by forming an ion-pair with the ionic glucuro­
nides at a higher pH. However, at a higher pH, the glucu­
ronides have been found not to be stable, so that ionic 
suppression was examined.
At a pH of 2.5» the effect of changing the eluent 
strength on the capacity factors and selectivity of the 
compounds and their glucuronides was studied (Table 5*4). 
Taking a compound and its glucuronide as a pair, the capa­
city factors were plotted against the % methanol in the 
mobile phase (figure 5*17)•
From these results, it is revealed that:-
(1) The hydrophobic stationary phase (-ODS) was found 
to be a suitable material since the separation was based 
upon the relative polarities of the glucuronide and parent 
compound, with the more polar compound eluting first. It 
was also an advantage to be able to elute the glucuronide 
before the parent compound because it ensured the ability 
to recognise completion of the analysis, especially impor­
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Column - Spherisorb-SODS.
(50x4.5 mm id) 
Column Temp. - Ambient. 
Detection - 2l4 nn 
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FIGURE- 5.17 Effect of Changing Eluent Strength on the 
Capacity Ratios of Some Commercially 
Available Compounds and Their Glucuronides.
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saving time. In contrast, in normal phase chromatography 
the glucuronides would elute last and might accumulate on 
the column thereby gradually degrading the column perfor­
mance  --
(2) The glucuronides were found to be stable at the 
pH of the mobile phase used, and they gave symmetrical 
peak shapes. Since most biological fluids were preserved 
in an acid pH, it was not necessary to adjust or alter the 
pH before analysis.
(3) Decreasing the % organic modifier was found to 
increase the retention and capacity factor as well as the 
separation factor of the glucuronides and the parent com­
pound (figure 5*i7)« Desired or suitable capacity values 
for analysis could thus be chosen from the graph - taking 
separation sind analysis time into consideration.
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5.3.2 Application.
This procedure could he applied to the carboxylic 
acids used as non-steroidal anti-inflammatory agents since 
no analytical method has been reported especially for 
simultaneous separation and identification of the agent 
and its glucuronide conjugate.
Large scale preparation of urine rich in glucuronide 
conjugate was prepared by dosing a healthy female rabbit 
with 600mg of Orudis capsule (ketoprofen) administered 
orally. The pooled 24-hour urine sample (about 150mls) 
was treated in the following ways:-
(1) 1ml diluted to lOmls with the mobile phase and 
after filtration, 2^ jllL was injected directly onto the 
column.
Acid hydrolysis of this diluted portion was carried 
out (figure 4.2) and after filtration 25^ was injected 
directly onto the column.
(2) An attempt was made to isolate the glucuronide 
from the urine by subjecting 3 0 ïïi1 s of urine to basic lead 
salt precipitation of Kamil, et al. (1951) (70). The 
yellow gum observed was dissolved in the mobile phase and
(i) 2 5 J^ 1 injected onto the column.
(ii) 2mls hydrolysed and 25JJ1 injected onto the 
column.
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(3) The free drug in 50inls of urine was removed by 
extraction into hexane at pH 2.0. The aqueous layer was 
then thoroughly shaken with 200mls of ethylacetate. The 
ethyl acetate was evaporated to dryness at 45^0 under 
vacuum and the brownish yellow gum obtained was dissolved 
in lOmls of mobile phase.
(a) 5ju1 from it was injected directly onto the column.
(b) 5Ju1 of the acid hydrolysed portion was also 
injected onto the column.
In all the 3 cases, similar chromatograms were ob­
tained, figure 5*18» suggesting that G was the glucuronide 
conjugate while D was the drug ketoprofen, Chromatogram B. 
After acid hydrolysis, chromatogram C further confirmed 
that G was the ketoprofen glucuronide and D the drug keto­
profen since the reduction in peak height of G and increase 
in peak height of D were remarkably noticeable.
Peak G was collected from the column and hydrolysed 
and tested for both the aglycone - the drug, by injecting 
onto the column to produce the peak of the drug. The 
hydrolysed extract was treated with:-
(i)^ /0.1^  freshly prepared alcoholic solution of car- 
bazole which turned purple (71),
(ii) Fehlings solutions 1 and 2 which turned brown.
These two tests suggested the presence of glucose.
Thus peak G is probably ketoprofen glucuronide.
FIGURE 5.18 Separation of Ketoprofen and Its Glucuronide 2 3 
Conjugate in Rabbit's Urine.
Column - SpherisorU 5”0DS 
(50x4.6mm id)
-Mobile Phase - MeOH-H^OAc
Detection - 260nm. 
Flow Rate - 2.Oml/min 
Column Temp Ambient
Time (mins.)
A - Control injection of ketoprofen 
S - Solvent front.
D - Drug - ketoprofen.
B - Injection of dosed rabbit’s urine.
U - Urine front.
G - Ketoprofen glucuronide.
D - Free ketoprofen excreted in urine.
C - Injection of hydrolysed dosed rabbit's urine.
U - Urine front.
G - Ketoprofen glucuronide - (much r.educed).
D - Free ketoprofen - (pronounced increase'after
hydrolysis)’.
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The process was repeated for another drug - henoxa- 
profen and similar results were obtained (figure 5*19)• 
Chromatograms A, B and C show the benoxaprofen glucuronide 
and free benoxaprofen.
Analysis of the.glucuronide was achieved on a reversed 
phase column with aqueous acidic methanol by gradually 
reducing the eluent strength to obtain a satisfactory 
separation.
Prior extraction or isolation of the glucuronide was 
not really desirable because of progressive loss of the 
glucuronide during the process. Attempts to obtain the 
glucuronide conjugates in crystal'form as described by 
Kamil^were not successful. However, concentration of the 
glucuronide conjugate was achieved by extraction into 
ethyl acetate evaporation to dryness, and then dissolving 
in a few mis of the eluent. This method was used by 
Harman, et al. (1964) (8).
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-FIGURE 5'19 Separation of Benoxaprofen and Its
Glucuronide Conjugate in Rabbit's Urine.
Column - Spherisorb 5-ODS 
(50x4.^mm id)











Control injection of benoxaprofen sample.
S = Solvent front.
D - Benoxaprofen.
Injection of dosed rabbit's urine.
U - Urine flront.
G - Benoxaprofen glucuronide.
D - Free benoxaprofen excreted in urine.
Injection of hydrolysed dosed rabbit’s urine.
U - Urine front.
G - Benoxaprofen glucuronide - absent.
D - Free benoxaprofen Cpronouneed- increase after
hydrolysis )'.
126
5.4 Field Desorption Mass Spectrometry»
Further attempts were made to confirm the identity of 
the peaks considered to be the glucuronides of ketoprofen 
and benoxaprofen. Field Desorption Mass Spectrometry of 
pure samples of ketoprofen, benoxaprofen and crude ex­
tracts obtained from urine considered to contain these 
glucuronides (figures 5*18 and 5*19) were obtained by the 
same instrumentation and experimental conditions as des­
cribed by Parfitt, et al. (19?8) (72) for gentamicins.
Spectrum 1, figure 5*20A shows the FD spectrum of a 
pure sample of ketoprofen (mol.wt. 254) with the parent- 
ion at m/e254. This could be due to ion A, which occurs 







Decarboxylation of ketoprofen would explain the pre­
sence of ion m/e209» i.e. (254-44).
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Spectrum 2, figure 5*20B, shows the FD spectrum of a 
crude ethyl acetate extract from the urine of a female 
rabbit dosed with ketoprofen. Attempts were made to inter­
pret the spectrum as follows.
m/e at 207 - Suggests a very stable ion, probably 
resulting from ketoprofen (m/e 254) or its proposed meta­
bolite (m/e 270).
m/e 254 - Corresponds to the free drug parent ion.
m/e 268 - Could be ketoprofen, as its methyl ester -
(253+ 15 * 268) caused as an artefact by the presence
of methanol in the extraction solvents.
The base peak,
m/e 270 - is strongly suspected to be a hydroxy- 
ketoprofen metabolite since it corresponds to ketoprofen + 
0 quasimolecular ion, i.e. (253+ 17)»
m/e 298 - This could then be the ethyl ester of 
hydroxy-ketoprofen, due to transestérification during 
extraction.
The presence of hydroxyketoprofen in urine has not
been previously reported. The position of the -OH group 
cannot be located from this spectrum, although NMR (^H aj 
^^ C) would offer evidence of the substitution position.
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Unlike the crude urine extract analyses on HPLC in 
figure 5'18, the FD speatrum shows no evidence of a glu­
curonide of either hydroxyketoprofen P+ m/e 447 or Q+ m/e 
448 or of ketoprofen /P—+ m/e 431 or Q**’m/e432). This could 
be due to hydrolysis of the glucuronide which could have 
occurred after extraction and prior to MS analysis, since 
there was a delay of several weeks.
However, HPLC analysis of a similar extract as shown 
in figure 5*18 strongly suggests a glucuronide, due to the 
change in peak heights after hydrolysis. Certainly, HPLC- 
MS, if available, would be a better technique, particularly 
under chemical ionization conditions. Spectrum 2 in figure 
5.20B could further explain the results in figure 5*18. It 
is very interesting to note that the acid hydrolysis com­
pletely eliminated the peak attributed to benoxaprofen 
glucuronide (figure 5«19C), but that a significant peak 
remains for ketoprofen glucuronide, figure 5«18C. Upon 
further examination of the ketoprofen glucuronide peak 
before hydrolysis, figure 5*i8B, a definite shoulder could 
be seen, suggesting the presence of a second compound. It 
is possible that this could be hydroxyketoprofen, which 
would be unaffected by acid hydrolysis.
These observations emphasise the need for an HPLC-MS 
analysis of the extract. Meanwhile, FD spectrum of pure 
sample of benoxaprofen is shown in figure 5*21 with the 
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The role of these new ionisation techniques especially 
soft ionization in MS is now being fully appreciated in ' 
clinical studies especially in drug metabolism where pure 
standards are not available (73»74). However, combined 
HPLC-MS (64,75) would be a powerful technique for the 
identification of a compound or metabolite directly as it 




This study has been a contribution to the analyses of 
non-steroidal anti-inflammatory agents in body fluids.
The recently introduced technique of HPLC has been used to 
develop simple and rapid analytical methods which would be 
suitable for- the routine examinations of plasma and urine 
in clinical situations.
Previously reported analytical methods employing 
spectroscopic techniques (Chapter 1.4) were non-specific 
and would not discriminate between closely related meta­
bolites . They are less suitable for pharmacological and 
pharmacokinetic studies because lengthy clean-up proce­
dures are required to minimize background absorption from 
endogenous materials.
B. Lotti (14) had shown that several analyses can be 
performed simultaneously using thin-layer or paper chroma­
tography but quantification is difficult. The recently 
reported gas chromatographic procedures for Alclofenac 
(75*7^)f Benoxaprofen (77)» Indomethacin (78), and Keto­
profen (79) have afforded a remarkable improvement in 
sensitivity. Like the previously reported GC methods, 
[Table 1.^ , derivatization is still very important to im­
prove their chromatographic behaviour. The use of mass
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spectrometry as a detector in GC-MS (76)■has further en­
hanced the already high specificity of GC. However, this 
instrumentation is at present too elaborate for routine 
application^— In general, GC methods are not applicable 
for the analysis of highly polar substances, such as the 
glucuronide conjugates. There is also a possibility of 
decarboxylation of some of the non-steroidal anti-inflam­
matory agents at the working temperatures employed in GC.
The HPLC procedure developed here has- advantages over 
all the previously reported methods in its simplicity and 
ability to cope with routine analyses of all these agents. 
Though it is possible for two of these drugs to have the 
same K' values in HPLC, the wider range of retention 
mechanisms and operating conditions available makes this 
less likely than in other chromatographic techniques.
Other advantageous features of this procedure arei-
1. Speed and Convenience: The analysis time ob­
tained for any of these compounds was generally about 5 
mins. This was possible because of:-
(i) The use of short columns of 50 to lOOmn having 
good selectivity and efficiency; and
(ii) The sample preparation has been kept to a mini­
mum. Unlike GC or other methods, direct injections of 
particle free biological fluids were possible. In certain 
cases where extraction was necessary, simple extraction
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procedures as described in figure 5*1 have proved very 
efficient and reproducible.
The use of an aqueous organic solvent on a reversed 
phase column permitted rapid mobile phase changes because 
of rapid re-equilibration. The packing of columns is 
easier than first thought; the use of toxic organic sol­
vents and derivatizing agents are not necessary. All 
these points have simplified the procedure to be conven­
ient for routine practices.
2- Sensitivity. By working at a fairly high sensi­
tivity of the detector, usually 0.02 absorbance unit per 
full scale deflection,( Aufs)^  and injecting 5iJl of the 
sample of each solute, detection limits between 2.5 and 
50ng for all the drugs were achieved. Table 5»1«
The level of the drug detected is a factor of: -
(i) The concentration of solute in the injected 
solution,
(ii) The coefficient of extinction of the solute in 
UV, and
(iii) The sensitivity of the detector employed.
The sensitivity obtained by this procedure is com­
parable with that obtained with GC. However, the sensi­
tivity could still be improved by: -
(i) Detection at the Amax. of the drug,
(ii) Direct injection of biological fluids, thus 
avoiding any extraction and evaporation procedures which 
could have caused some loss of the solute.
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(iii) Injection of large volumes, 25» 50 or lOOjul of 
the sample. Loss of resolution by injecting up to 50xH 
or even lOOjLil is slight, even for short columns, because 
the injected volume does not expand as in GC.
(iv) Concentration of the compound, only when neces­
sary.
Higher sensitivity could be obtained by derivatizing 
the compounds for either UV or fluorometric monitors. 
Jupille (80) and Ahuja (81) have reviewed derivatizing 
agents for carboxylic acids. These compounds are high 
dosing drugs and their concentrations in urine and plasma 
are high enough to be easily detected and quantified with­
out derivatization. Thus derivatizing these drugs was 
found not only unnecessary but also time consuming and 
expensive.
The HPLC procedures developed have been used in the 
analyseg__of non-ataroidal anti-inflammatory agents in body; 
fluids as follows;-
(1) The determination of ten non-steroidal anti­
inflammatory agents in plasma and urine (82,83)»
(2) This procedure was used frequently to assist 
clinicians at one Bath hospital to provide rapid evalua­
tions on patients' compliance.
(3) It has also been applied in the clinical trial 
of benoxaprofen at the Royal National Hospital for
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Rheumatic Diseases in Bath (84). This clinical trial was 
carried out in ten in-patients administered with 600mg of 
the drug once daily for seven days. Their blood and 24- 
hour urine samples were collected at the same time for 
analyses. The range of the drug level in plasma was 
between 76 and lyOug/ml. This trial demonstrated that 
the drug possessed both analgesic and anti-inflammatory 
effects and was well tolerated. The efficacy parameters, 
articular index and duration of morning stiffness were not 
well related to the level of the drug in plasma. Non­
steroidal anti-inflammatory agents are a group of drugs 
that do not show a correlation between blood levels sind 
efficacy (85). However, the blood levels of these drugs 
relate well to the dose, side-effects and also confirm 
that the drug is being taken by the patient. Further work 
is in progress in an attempt to relate their blood levels 
directly with their efficacy, or with other measurable 
parameters, such as plasma protein sulphydryl levels.
(4) The simultaneous determination of four non­
steroidal anti-inflammatory agents and their metabolites 
in plasma and urine (8^ ).
(5) The profile study of the levels of sulindac and 
its metabolites in plasma of a healthy volunteer after a 
single oral dose over 24 hours (Chapter 5*2.2, figure
5.12).
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(6) The examination of clinical urine and plasma 
-samples of a patient receiving clinoril and naproxen
drugs (Chapter 5*2.2, figure 5*13)*
(7) The separation of the glucuronide conjugates of 
ketoprofen and benoxaprofen (5*3)*
The primary objectives of this research have thus been 
accomplished. The procedure has been recommended to our 
local hospital, The Royal National Hospital for Rheumatic 
Diseases, Bath, and will lead to the installation of 
suitable HPLC instrumentation in the hospital for routine 
clinical investigations.
This procedure could still be improved by the use of 
a highly specific detector, mass spectrometry. This will 
help to simultaneously identify all the separated com­
ponents in the absence of their standards.
The success of this work has been largely due to the 
detailed study of the instrumentation of the HPLC tech­
nique. This has enabled essential modifications o-f the- appara­
tus ussd, especially the coil damping system and useful, plumb­
ing connections and by-passes, to be improvised and proved 
successful. The repairs and maintenance of the instru­
ments have also been carried out during experiments and 
it is now simple to diagnose, detect and improve faults 
in the instrumentation by mere examination of the chroma­
togram. This is an important consideration since this
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technique will be further explored for pharmacological, 
biochemical and clinical studies in a developing country, 
like Nigeria, where technical assistance, at present, is 
scarce.




Details of individual experiments have been included, 
as appropriate, to link with the relevant results and dis­
cussion in the proceeding chapters.
The following (a) itemises the nature and sources of 
chemicals and apparatus used, (b) provides a commentary on 
available HPLC instrumentation, and (c) gives details of 
chromatographic operating procedures and methods of quanti­
tation used in the present work.
7.1 Nature and Sources of Chemicals and Apparatus Used.
7.1.1 Reagents.
Methanol, acetonitrile, hexane and isopropanol, all 
HPLC-grade, obtained from Rathbum Chemicals, Walkerbum, 
Scotland, Ethyl acetate analar grade, sodium hydrogen phos­
phate, and glacial acetic acid from Fisons Scientific 
Apparatus, Loughborough, England. Hydrochloric acid (cone) 
and sulphuric acid (cone) from B.D.H., Poole, England. 
Cetyltrimethyl ammonium bromide (cetrimide) from Imperial 
Chemical Industries, Macclesfield, England. ^-glucuroni- 
dase/arylsulfatase enzyme from Boehringer, Mannheim, Germany.
*
Where first experimental detail appears in Results and 
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7.1.2 Drugs. „ 142
Pure standards of drugs used were generously donated
by.the companies.listed in Table 7.1.
7.1.3 HPLC Hardware.
1. HPLC Pumps.
(1) Mini-Pump^'Milton Roy Company, Model 396 of 
Laboratory Data Control, obtained from Phase Separations
Ltd. 'r-
(2) Jobling HPLC Model JLC 202 fitted with Haskel 
Dst 122 Pump. Jobling Laboratory Division, Stone, Staf­
fordshire, England.
2. Detector- Variable wavelength - UV Detector,
Cecil Instruments CE212. Milton Industrial Estate,
Cambridge, England.
3. Recorder; Venture Potentiometric flatbed Servo- 
scribe. Is Re 541.20, Smiths Industries Ltd.
4. Integrator:- Venture Digital Integrator MKll 
supplied by Phase Separations Ltd.
5. Injection Valve:- Specac Dual Volume Injection 
Valve 30.003/30.004 with a fixed operational internal 
cavity injection of 5^1 and interchangeable external loop 
of 25» 50 or lOOjul. Supplier - Spectroscope Accessory 
Company, Sideup, Kent, England.
6. Columns - Column tubings, end fittings and plumb­
ing and fitting kits were obtained from HETP, 34 Gonville 




(i) Spherisorh 5-ODS - Phase Separations,
(ii) Hypersil 5-ODS - Jones Chromatography,
(iii) Hypersil 5-SAS - Jones Chromatography.
(2) Bonded silica - normal phase.
(i) Spherisorh 5NHg - Phase Separations,
(ii) Hypersil APS - Jones Chromatography.
8. Solvent delivery system.
This ideally contains solvent reservoirs, pumps, 
gradient elution device, pressure indicator, flow meter 
or controller, pulse damper where necessary and in-line 
filters.
(i) Solvent reservoirs - Glass containers are usually 
convenient because they are transparent, corrosion proof, 
inert with respect to the solvent although fragile.
7.2 Commentary ~ on Available HPLC Instrumentation.
7.2.1 Pumps.
There are two- types of pumps in common use:-
(i) Constant pressure - Coil
- Pneumatic amplifier 
- (ii) Constant flow - Reciprocating - Single piston
- Dual piston.
(i) Constant pressure pumps - These consist of some 
form of pneumatic device for the direct pressurization of
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the mobile phase with an inert gas, usually nitrogen.
They give a reliable pulse-free flow but the flow-rate and 
hence elution volumes can vary with changes in permeability 
of the column or viscosity of the solvent. Examples are :-
(a) Pressurized coil pumn - It is the simplest form 
of pump, consisting of a stainless steel coil filled with 
the mobile phase andregulated nitrogen pressure used to 
drive the liquid through the column, figure 7.IA.
It gives an absolutely pulse-free flow. In practice, 
it is cheap with minimal maintenance cost, convenient for 
routine analysis where the same or similar solvent systems 
often used. But changing solvent is much less convenient.
(b) Pneumatic amplifier - These pumps operate at a 
constant pressure chosen within a range of IOO-50OO psi 
and the flow rate emerging from the detector is dependent 
upon the resistance to flow within the entire system. 
Adjustment of pressure produces the required flow rate 
which remains pulse free except during the 2 secs required 
for the automatic refilling step.
Pressure from an external source, usually nitrogen 
cylinder, is supplied to a large surface area gas piston 
attached to a smaller surface area hydraulic piston, 
figure 7.IB. Thus the applied pressure is amplified and 
a column pressure of ^000 psi can easily be obtained with 
a 100 psi gas supply. The gas pressure is released at the
145
FIGURE 7.1








B, Pneumatic Pressure Intensifier (eg. Haskel DST.122) 
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end of the delivery stroke and the solvent vessel refills 
by the action of gas pressure or a spring. Check valves 
between the solvent chambers and the column, prevent the 
back flow during refilling.
Since they can produce high flow rates (75mls min” )^ 
and high pressures from the moment they are switched on, 
they are very successful in preparative HPLC and column 
packing techniques.
Their major disadvantage is the time and volume of 
solvents wasted when the composition of the mobile phase 
needs to be altered.
(ii) Constant flow pumps - These are either metering- 
type pumps, normally mechanical reciprocating devices, or 
a large syringe-type system. The reciprocating pumps are 
relatively cheap and incorporated in many commercially 
available instruments.
They naturally give constant flow. Small piston 
types often have constant speed motors synchronized to the 
supply frequency. Flow rate is altered mechanically by 
adjusting the piston stroke length; and they can keep 
pumping as long as liquid is available without a long 
pause to refill (figure 7.2A).
Disadvantages of these pumps are:-
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(b) Pulsating flow which can give rise to consider­
able base-line instability.
Pulsating flow has been overcome by various devices 
referred to as * Damping' which smoothen the flow of sol­
vent delivery to the head of the column by;-
(a) A dual or triple-piston pump (figure 7.2B);
(b) A spring-like tube containing 10ml of air, and 
introduced daily before pressurization with the pump. 
This was used during these studies (figure 7*20).
(c) A flexible bellows or tube, and
(d) A restrictor.
Table 7»2 compares the characteristics of different 
pumping systems.
7.2.2^  Sample injection valve.
Valve injections are capable of introducing very 
precise volumes of the sample into the chromatographic 
system. A fixed volume loop is filled with the sample 
dissolved in the mobile phase, and by turning the shaft, 
the loop is placed into the solvent stream in front of 
the column (figure 7.3A).
Sample valves are very convenient and reproducible 
because injection occurs at the column pressures and all 
the sample is swept onto the column, by the mobile phase. 















FISÜHEÏ.7.3 (A & B) Injection Systems
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volume. The injected sample travels some distance in the 
mobile phase before reaching the column, causing some 
dilution of the sample by the mobile phase. This reduces 
the sensitivity, peak shape and efficiency of the column 
obtained compared with syringe injection. In general, 
syringe injection produces five times the sensitivity and 
twice the theoretical plate number compared to valve injec­
tion.
7.2.3 Column.
The design, construction and fittings required are 
discussed under column packing (7*3)•
7.2.4 Detection.
Chromatographic detection is a device which indi­
cates the presence of and measures the amount of separated 
compounds in the column effluent. The twojb^ic types of 
detectors are
(1) Bulk property detectors which measure an overall 
change in physical property of the mobile phase, eg., 
refractive index and conductivity techniques.
(2) Solute property detectors which respond to a phy­
sical property of the solute which is not exhibited by the 
pure mobile phase, eg., ultra-violet (UV) light absorption 
and polarographic techniques.
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Important characteristics defining the detector per­
formance are : -
(i) Noise - which is the random signals interfering 
with the measurement, the frequency of noise compared to 
the band-width or frequency range of the measurement 
determines how much noise interferes. Noise limits sen­
sitivity and measurement accuracy, thus minimal noise is 
required.
(ii) Response. This is the slope of the calibration 
plot of detector signal against solute concentration or 
mass rate. Noise, stray light and error in zero trans­
mission setting leads to non-linearity.
UV detectors are commonly used in HPLC because they 
are selective and frequently have high response. UV moni­
tors with the full-range spectrometers are preferred, 
because they offer greater versatility. They are little 
affected by environmental changes and so arerather easier 
to use than many other detectors. Short column-to- 
detector connection with low dead-volume cells (10 jul) is 
usually desired since the volume in the flow cells deter­
mines the minimum volume that can be sampled but lack of 
ideal flow through the cell adds markedly to the zone 
spreading caused by the cell.
The flow-through cell could be adversely affected by 
gas bubbles issuing from the column which either pass
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through, or are trapped in the detector flow cell. This 
problem is best eliminated at the source by thoroughly 
degassing the mobile phase before use or by applying a 
small back-pressure on the outlet of the detector cell by 
the thumb or by a capillary restrictor.
7.2.5. Recorder.
The subsequent detector signal is amplified and 
passed to a potentiometric recorder to obtain a permanent 
record of analysis in the form of a chromatogram.
For this work, both Haskel and Mini-pumps were used 
to deliver a pulse-free solvent. It was necessary to 
develop a "home-made" air-coil damping system used with 
the Mini-pump to obtain a pulse-free solvent flow. The 
Haskel pump was also used to pack all the columns used 
in this work.
A variable wavelength UV detector (Cecil Instruments) 
was used throughout as the monitor and sample injection 
was by Specac dual volume injection valve already des­
cribed.
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7.3 Column Packing and Testing.
The quality of a column is determined by its effici­
ency, principally governed by the packing density and the 
particle size. The main objective of column packing is to 
reduce band spreading. Prepared columns are commercially 
available but very expensive. Packing columns allows the 
free choice of column length to reduce analysis time and 
is very economical.
7.3.1 Packing Procedure.
The packing equipment that has been used in the--dia­
gram, (figure 7'4CJ gave consistently reproducible results 
with a large number of columns (87,88). All columns used 
for these studies were prepared from i" OD, 4.6mm ID. 
Stainless steel tubings. An appropriate length of tubing 
is cut evenly, the ends are smoothed and deburred, and 
washed with acetone and methanol. A column terminator 
with a stainless steel frit of 0.5 to 2um porosity was 
fixed to one end of thetubing, using standard low dead 
volume connectors, and the column is ready for packing, ' 
figure 7.4a.
The dilute slurry technique proposed by Bristow, et 
al. (1977) (89) was used. Silica, (1.3-1.4gm per 100x4.6 
mm ID column) was dispersed by shaking vigorously in 
of methanol, and immediately poured into the slurry reser­
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reservoir and the whole was mounted vertically with the 
reservoir and the column now inverted, figure 7,4C. The 
pump was pressurized up to the on/off valve to a liquid 
pressure of about 4000 psi, and the valve opened. About 
250mls of the solvent was passed through after which the 
pressure was turned off, the solvent flow was allowed to 
fall to zero and the column left for about 5 minutes 
before the column was carefully removed.
About 10mm of the packing was removed from the top 
of the column, terminating it with a suitable metal frit, 
adding about of glass ballotini beads (75-150jum) and 
the column was finally smooth-sealed with a porous PTFE 
plug. The column is thus ready for use after condition­
ing with the desired eluent.
7.3.2 Column Testing.
All columns used in this work were tested for their 
efficiency by an accepted standard procedure proposed by 
Bristow and Knox (1977) (90). A typical chromatogram is 
shown in figure 1.15 for a 50mm column packed with Spheri- 
sorb, 5-ODS; plate heights (H) of about 0.025nnn and re­
duced plate heights (h) of about 5 were usually obtained.
The same method was used to monitor column efficiency 
and to indicate any deterioration as a result of injecting 
biological fluids and large numbers of samples.
Dirty columns were regenerated using pure methanol 
at a flow rate of Iml/min for about an hour.
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7.4 Types of Reversed Phase Columns.
C.M. Riley, et al. (1979) (91 ) and others (41,47^88, 
92) studied the contributory role of commercially avail­
able reversed phase stationary phases. The effects of 
chain length, carbon content, extent of derivatization 
on wetability, retention and selectivity were examined by 
them. Three commercially available reversed phase packing 
materials - Hypersil. 5-SAS, Hypersil 5-ODS and Spherisorh 
5-ODS, figure 5*2 - were investigated here and further 
confirmed that: -
(i) The order of elution of non-steroidal anti­
inflammatory agents in all reversed phase systems using 
the same mobile phase conditions is generally the same.
(ii) Retention and selectivity is increased by 
increasing the % carbon content bonded to the silica.
(iii) The surface concentration of accessible silanol 
and siloxane groups also attributes to differences in 
retention.
Fully silanized accessible OH groups and high carbon 
content as in Hypersil 5-ODS contribute its higher K' 
values and better selectivity compared to Spherisorh 
5-ODS. The retentive power of the reversed phase station­
ary phases has been ranked as Partisil ODS-2 > Hypersil CDS? 
Spherisorh ODS> Spherisorh Hexyl> Partisil CDS, and has 
been related to the carbon loading of these supports.
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A - Spherisorh 5-ODS 50 x 4.6mm id.
B - Hypersil 5-SAS 50 x 4.6mm id.
C - Hypersil 5-ODS 50 x 4.6mm id..
Mobile Phase - Methanol : Water (50:50)
Detection - 254nm.
Volume Injected - 5lil.





However, irrespective of the type of reversed phase 
column used, high selectivity can be achieved by careful 
selection of the strength of the eluent.
Figure 7.7 illustrates the summary of interactions 
on reversed phase.
FIGURE 7.7 Summarv of Interactions on Reversed Phase.
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7.5 Procedures
7.5.1 Preparation of Mobile Phase.
HPLC grade solvents were used for the mobile phase. 
Each component volume was measured separately before mix­
ing. This ensured reproducibility and accuracy since many 
solvents when mixed do not give additive volumes due to 
solvation effects. All mobile phases were freshly pre­
pared to eliminate the possibility of contamination or a 
change in concentration, especially when buffers and 
counter-ions were present in the mobile phase.
The prepared mobile phase was filtered using a 
micropore 0.4iim membrane to remove particles which tend 
to block the:plumbing system, especially the injection 
valve, then degassed either by refluxing for a few minutes 
or by passing Helium gaa through it for 5 minutes. It is 
then adjusted to the required pH - usually pH 3 or 2.5 - 
by titration with glacial acetic acid.
7.5.2 Preparation of Stock Solutions of Standards.
Stock solutions of the drugs used as standards were
prepared by accurately weighing lOmg of each sample and 
dissolving it in lOmls of ethanol to give a strength of 
Img/ml. Suitable concentrations desired were then pre­
pared by further dilutions using the mobile phase.
164
7.6 Principles of Quantitative Analysis.
Accuracy and a high degree of precision in quantita­
tive HPLC is associated with the following parameters.
1. Injection of the sample. This is achieved by 
using a syringe or injection valve. It is of paramount 
importance to introduce the precise volume required 
directly onto the column. This is difficult but possible 
using a valve injector, but not generally possible with a 
syringe. For accurate quantification in the absence of 
an internal standard it is essential that very accurate 
injection volumes are obtained.
2. Column and its operational parameters. Column 
efficiency is very important since it governs the sym­
metry of the peak. Also, the flow rate must be kept con­
stant since peak area is inversely proportional to flow 
rate. Pressure fluctuations in the system have an adverse 
effect on peak area measurements (93»94).
3. Detector response. This is defined as the slope 
of the calibration plot of the detector signal against 
the solute concentration. For high precision, the detec­
tor response should be linear passing through the origin, 
i.e. obeying Beer Lambert's Law.
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7.6.1 Measurement of Detector Signal.
Once the desired separation has been achieved, the 
response from the detector representing the mass of solute 
can be.calculated using
(i) Peak height,
(ii) Peak area, by hand planimeter or by electronic 
integration,
(iii) Cutting and weighing; and
(iv) Triangulation.
From these methods, electronic integration of peak 
area and peak height measurement have been considered.
The precision of repeated injections of a mixture of 
phenylbutazone, paracetamol and 2,4-dinitrobenzene (figure 
7.8) by comparing the peak height measurement and elec­
tronic integration of the peak area were compared (Table 
7.3A)» In both methods, an internal standard (Table 7«3B) 
to compensate for minor variations of injected volumes. 
They both gave a marked reduction in the % coefficient 
variations from 8$^ to 3% 'or" less.
Both methods proved to be reliable and suitable for 
measuring the detector signal with a high precision. The 
choice of a method was then based on the reliability of 
the electronic integrator employed and with its cost, 
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TABLE
(A) Measurement of the Peaks in Terms of Peak










fo C . Y ,
+ 8x100^ 
fli
Height 5 48.400 3.11 6.63
1
Area 5 20628 1431.90' 6.94
Height 5 67.60 2.30 3.41
2
Area . 5 35548.8 2574.37 7.24
Height 5 87.80 3.36 6.10.
3
Area 5 55873.60 4233.8 7.38.
(B)_____Measurement of the Peaks in Terms of Peak














Height 3 0.33- 0.01 0.82 .
1
0.96Area 3 0.37 0.0 1
Height 3 0.77 0.02. 3.03
2
Area 3 0.64 0.01 0.8 2
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With either method, some basic errors have to be 
prevented:-
With peak heights:-
(a) Placing of the base line, and
(b) Measuring the height from the base line to the
apex of the peak are very significant.
With peak area:-
(a) Placing of the base line in the correct position,
(b) Measurement of the height from the ,
baseline,
(c) Placing of the line and its measurement parallel 
to the baseline at half peak width, and
(d) The measurement between the doping sides of the
peak.
Calibration plot (figure 7*9A) of the peak height 
ratio and peak area ratio of indomethacin to the internal 
standard - 2,4-dinitrobenzene versus the concentration of 
indomethacin showed the resulting or regression line 
(figure 7«9B) to be straight and passing through the 
origin, that is obeying Beer's Law - the intercepts in 
both cases are not significantly different with zero. 
Correlation coefficient in both cases are 0.9997 and
0.9998 for peak height ratio and peak area ratio measure­
ments respectively.
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FÎGURE 7.9A Calibration of Peak Height Ratio and 





Column : - Spherisorb ^-ODS (200x4.6mm id)




S - 2,4-Dinitrobenzene (Int. Std.)
1 - 5jug/ml of Indomethacin
2 - lOjjg/ml of Indomethacin
3 - 2 0jjg/ml of Indomethacin
4 - 40jjg/ml of Indomethacin
5 - 80jug/ml of Indomethacin
Volume Injected - 5JLil.
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TABLE 7 >-6' L -
(A) Calibration Plot of Peak Height Ratio and 
Integral Ratio for Quantification.of Indp- 




(Ug/ml) 1 2 3 4 Mean
Height
80
1.82 1.90 2.00 2.03 1.94
Area 1.30 1.37 1.32 1.33 1.33
Height 0.99 0.89 0.90. 0.91 0.82
40
Area 0.67 0.60 0.62 0.63 0.63
Height 0.49 0.46 0.46 0.46 0.46
20
Area 0.33 0.31 0.31 0.31 0.32
Height
10
0.23 0.23 0.22 0.23 0.23
Area 0.15 0.15 0.15 _ 0.15
Height
5
0.12 0.12 0.12 - 0.12
Area ' 0.06. 0.07 0.07 --- — 0.07 .





Slope , 0.02 0.02
Intercept -0.02 -0.02
Correlation Coefficients 1.00 1.00
When n = 7*5 y = 0.16. 0.10
When n = 70.0 y = 1.68 1.15
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FIGURE-7»W  Calibration Graph of Peak Height Ratio and
Integral Ratio for Quantification of 
Indomethacin (I) Using 2,4-Dinitrobenzene(D) 





Cone of Solute (/jg/ml)
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Most of the quantification in this work has been 
based on peak height measurements and have produced low 
coefficients of variation. It has also allowed minor 
variations in the flow rate not to interfere with the 
precision and quantification.
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7.6.2 Precautions in Quantitative and Qualitative HPLC.
For: -
1. High Precision of Measurement in Quantitative 
Analysis, the following precautions were usually taken.
(i) Column flow rate was kept constant.
(ii) Solvent composition was prepared accurately.
(iii) Quantification was made at low noise-level of 
the detector, and
(iv) Well separated symmetrical peaks were quantified.
Experience has shown more than 50% of the total error
of reproducibility was caused by faulty injection tech­
nique. Control of column temperature would further improve 
reproducibility of the separations obtained.
2. Trace Analysis. The elution power of the column 
and the detection limit of the detector were usually 
employed to obtain sufficient separation within minimum 
retention. Thus the need for:-
(i) An efficient column, obtained by choosing a 
selective packing material, and
(ii) Reducing the retention time by choosing a column 
as short as possible, eg. 50nmi.
A P P E N D  I C ES.
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APPENDIX I 
Calculation of Drug -Recovery
% Recovery of drug from spiked biological fluid is 
usually expressed as:-
Amount Recovered „ ,
‘ Amount Spiked ^
But for good precision and accuracy, recovery has 
also been expressed as % recovery over the concentration 
range of drugs spiked in urine or plasma in the form of a 
calibration slope.
Typical results obtained from calibrations and 
recoveries of Ketoprofen from spiked urine and plasma are 
shown in Table AI, with the chromatogram already on 
Figure 5^2
With the calibration plots of the recovered drug 






where A = Drug in mobile phase
B = Drug extracted from plasma 
C = Drug extracted from urine.
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TABLE AI -
03 5P.-<J1 Q:?Prtjn .Li5T3Q5> 179S oPHrJlG 0< 36 11:30: 34 12/04/79 022000
03 £0 3 00 4C025 1A8 0 0 0 l 11:31:51
:-'l TA3X or Cl 79 S) IND3
^// TYPE S 
PEPE.AT
?// TYPE DSET99C61Q05
FJXTRAN [V PkOGRAM SHMOOl CGÜMPOSEO A3 3 P A J 1 1037303) STAPTED 12/04/79 11
: 1 0 : 4-5
EXPERK aENT NUMBER ELUENT
DATA XTYPE= 3 YTY P E = 0
.< v a l u e  Y VALUE X TYPED Y TYPED
7260 INVALID CHARACTER.
SHMOOl TERMINATED ON 12/04/7 9
CURRENT DATA SET RE". NO. IS 97
CURRENT FORMAT STATEMENT IS: CSG10.4)(4E1
. [.
POINTER IS AT CHARACTER 6 
RECORD BEING PROCESSED IS : "PLASMA 5 1 0  0
« C .
POINTER IS AT c h a r a c t e r  C
CONTROL WAS IN 1/0003R
(LEVEL n  AT LOCATION 0224DE>= PROG. ORIGIN *000C?6 = I/0002R*OC39CA 
ARG. A5S. PROG. SY m =QL!C
NO. LOG AD0R3 LOCATION TYPE HEX VALUE VALUE
GRAPHICS
01. 2322G CODCS S H M O C 1*GGDC? RG F0F5C560F043F1F2 -6.007=97694:09009 
D 57 0 5 - C . 13
WAS c a l l e d  BY SHMOOl, COMPILED 26/07/76 BY VERSION 30 . STATEMENT CARD 
NUMBER 001 !
FORTRAN IV p r o g r a m  SHMOOl (COMPOSED AS BPr. JI 1LSTSQS > STARTED ! 2/04/79 11 
: 30:53
e x p e r i m e n t  n u m b e r  ELUENT 
DATA XTYPE= C YTYPE= 0
X VALUE Y VALUE X TYPED Y TYPED
Q . !500000D 02 G.25SÔ0C0D Cl Q . 1500000D 02 0.25360000 01
Q . 1OOOOOOD 02 0 . 1 7120GOD 01 0.1OOOOOOD 02 0. 17 !2000D 01
0 . 50COOOOD 0 1 0.32 1COOOD 00 0-50000000 01 0.F 2 100000 00
0.25000003 0 1 0.401OGGCD 00 0.250OGC0D 01 0.401OOOOD 00
0.125COOOD 0 1 0. 1 34000CD 00 0 . 1250000D 0 1 0.13400000 00
3UMX ALL SO = 0.11390630 Ü4 
SuMf h LL s o  = 0.3253562D 02 
SUMX3Q = 0.35731250 33
SUMY 33 = G. I 0 4 3 7 0 4 0  02  
SAX = C.130000CD 33
3XY = C.2 27 4 5 500 02  
SYY = 0.3 9 7 = = 15D Qi
SLOPE = 0 . 17496543 00
: sTE'CEPT= -C.402 !635D-0I
CORRELATION COEP-ICIENT= 0.99996990 GO 
ST4N04RD DEVIATIQN OF SLOPE = g.7=39=290-03 
5T^nDA-;D DEV I AT 10:', OF I\TERCEPT= 0.-63 I 2 2 R 3 - C 2
(Table Al - continued)
EXPERIMENT NUMBER PLAS^ a 
DATA XTYPE= 0 YTYPE= 0
17 6
X VALUE Y A L J u X t y p e d Y TYPED
0. 150G000D 02 0.25 5 ; GOOD 01 0.150GG00D 02 0.25310000 D 1
0.1OOOOOOD 02 0 . 1 5G2C00Q 01 0.1OCOOOCD 02 0 . 1 302G0CD 0 1
0.50000000 0 1 0. 76900C0D 00 0.50000000 0 1 0.76900000 00
0.2500000D 0 1 0.3650C00D 00 0.25000000 0 1 0.36 500000 on
0. 12500000 0 ! 0 .14 9 00000 00 0.12500000 0 1 0.14900 300 0 '
MX ALL SO = 0 .1139063D 0 4
SUMY ALL SG 0.321Q336D 02 
03SUMXSQ = 0.3573 125D
SUMYSO = 0.1065555D 0 2
SXX = 0.13000000 03
SXY = 0.23433250 02
SYY = 0.42348410 01
SLGPE = 0 . 1 802553D 00
INTERCEPTS -0.33 525440-0 1 
CORRELATION COEF-ICIENT = 
s t a n d a r d  DEVIATION OF SLOPE 
STANDARD DEVIATION OF INTERCEPT:
0.99371670 00
0 . 5277503D-02 
0 .44544340-0 !
EXPERIMENT NUMBER ELUENT
DATA ,<TYPE= 0 YTY^E= 0
X v a l u e
]. I 500C0CD- 02 
0.!OOOOOOD 02 
0.50000000 0 1 
j.25000000 0 1 
0. ! 2500000 0 1 
SUMX ALL SO s
Y VALUE 
0.2 7C9C00D 0 1 
0 . 1 3 5 lOOOD 01 
0 . 9370000D 00 
0.4 77 70000 00 





0.50000G0D 0 1 
0.25000000 0 1 
0.12500000 0 1
Y TY.^ED 
0.27090000 0 1 
0. 136 ! 0000 01 
0.94700000 00 
0.4 7 77 3000 00 
0.23700000 00
SUMY ALL S3 = 0.3 9334220 02
SUMXSO = 0.35731250 03
SLMYSa = 0.12060540 02
SXX s 0.13000000 03 
SXY = 0.2333653D 02
SYY = 0.41936930 01
SLOPE = 0.1795 1170 00
INTERCEPT: 0.42635320-0!
CCRRELATIGN CCEF"IClENT= 0.99946130 0 3
STANDARD DEVIATIEN OF SLOPE = 0-34017790-02
STANDARD DEVIATION OF INTERCEPT: 0.23777220-01
EXPERIMENT NUMBER URINE EXT 
DATA XTYPE: 0 YTYPE: 0
X VALUE Y VALUE X TYPED Y TY=ED
0.15000000 02 0.270GO0CD 0 1 0.15G3000G 02 0. 270000^0 3 !
0.1OOOOOOD 02 0. 1 920000D 01 G.lOOOOCOD 02 0. 1 9 2 0 0 0 0 D 0 1
0.50000330 0 1 _ 0.89C000QD 00 0.50Q0000D 01 0. 390:0:30 I'C
c . 2 5 0 0 0 0 0 0 0 1 0.5D50C30D 00 D.2 5 0 0 0 : 0 3 0 1 0. 505GG0GD
T.  12530003 0 1 0.234CDGDD 00 0 . 1250300D 0 1 0. 234000CD ■DO
SUMX ALL S3 
SUMY ALL S3 
SUMXSQ : 0-
SUMYSO : 0.




SXX : 0.13000000 03
SXY : 0.2352425D 02
SYY : 0.4 26 32 51 D 0 1
SLOPE : 0.137955-0 00
INTERCEPT: 0.2 = 349 5 60-0 i
CORRELATION COE== IC I E'.T = 0.99365 990
STANDARD d e v i a t i o n  0= SLOPE 
STANDArtD d e v i a t i o n  OF INTER DEPT:




’// "D-DEL DSE T (5 5 ICC) 
3202 BPR Jl 1.D 5 E T (561 :D) 
’ // MD = OEL n S F T = 7 (6 < CO 1
- NO F DEL 
?// LOCO
I I . - . 3  E T  u
JzET
USED E :J LE= =4475'
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% Recovery over the range of concentration is then 
expressed as:-
r  °
The slopes, intercepts, correlation coefficients, 
standard deviations of the slopes and intercepts could be 
obtained from the computer program. Table AI, t-test of 
the slopes shows no significant difference between them 
and the recovery is total.
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APPENDIX II 
Calculation of Linear Regression
All calibration plots were obtained by calculating 
the linear regression based on the linear equation of the 
form y =: mx + b, (Figure A2 ).
(Peak Ratio)
X (Cone, in jug/ml. )








b = y-nîx, 











After the linear regression is determined, the 
degree of association between the random variable (xi,yi)
 (xn,yn), known as the correlation coefficient (r),
could be calculated using the expression
r = m<rSc^
2
where <Ty = Variance of the y values
Z y ^
1-1 —  y
N
These tedious calculations had been avoided by using 
a scientific calculator, Texas Instruments, SR-51-II or a 
computer which automatically computes all the required 
data, viz:- the slope, intercept, correlation coefficient, 
mean, standard deviation and variance. Table 7*6
Typical program obtained for data on Table 7»6 using 




FORTRAw I V PRC3KA.X 3H.YG01 (COMPOSED AS 3PH J i 1 LSTSQS ) STARTED 30/01/79 1 A 
: 37:36
EXPERIMENT NiJ->3E= PEAK KT.OT ^





0 - 1 0 0 0 0 0 0 0  
0.500000 00 
SuMX all so : 









0. I ! 300000 











S'JMYSl = 0. 4 3504 32 0
SXX = 0.3 7200000 04
SXY = 0.9 0254000 02
SYY = 0.21925 710 0 1
SLOPE = 0.2426 9390-01
INTERCEPT: -0.19166670-01 
CDPPELATIDN CDEE-ICIENT: 
STANDARD OEVIATIGN E“ 
STANDARD OEVIATICN OF
X TYPED Y TYPED
0-30000000 02 0. I 9 3 7000D 01
0.40000000 02 0.92200000 00
0.20000000 02 0.461OOOOD 00
0.1OOOOOOD 02 0.22500000 00
0 . 5C00000D 0! 0.1!500000 00
0.99963350 00 
SLOPE = 0.35264340-03
INTERCEPT: 0.145612 2 D - C 1
EXPERIMENT NUMBER PEAK AREA
d a t a  XTYPE: 0 ''TYPE: 0
X VALUE Y VALUE X TYPED Y TYPED
0.800000 00 02 0.13300000 01 0.30000000 02 0. 13300000 01
0.40000000 02 0.631OOOOD 00 0.40000000 02 0. 631OOOOD 00
0.200000CD 0 1 0.3 17OOOOD CO 0.20000000 0! c. 31700000 00
0.1OOOOOOD C I 0 . 1 490ÛOOD 00 0.1OOOOOOD 0 1 0. 14900000 00
0.50000000 0 1 0.6 7700000-■01 0.50000000 01 0. 67700000- 01
SJMX ALL SQ : 0.16384000 05 
SUMY ALL SQ % 0.62235230 01 
SUMXSQ : 0.80300000 04
S'JMYSQ : 0.22943340 0 1
SXX : 0.4 7 53200 0 0 4
SXY = 0.63397150 02
SYY : 0. 1 0496290 0 1
SLOPE : 0.14494900-0 1
INTERCEPT: 0.12737040 OC
CORRELATION CG E FF ICIENT = 
STANDARD 0 EV lA T IGN OF SLOPE 
STANDARD OEVIATIGN OF






?// NDADEL DSET9«C61G01 
?// LOGGjT 
1 4 . 5 9  ETU USED = 00 ETJ LEFT 945456
Bl BL I OGR A P H Y  
AND  
R E F E R E N C E S -
±BX
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